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Plasmodium falciparum and Toxoplasma gondii are human parasites that belong to the 
phylum Apicomplexa and are the causative agents of malaria and toxoplasmosis, 
respectively.  These parasites infect billions of people annually worldwide causing 
significant morbidity.  We made use of biochemical and biophysical methods to better 
understand essential fatty acid metabolism of these pathogens, such as Fatty Acid 
Synthesis type II (FAS-II) and lipoate metabolism.  The apicoplast, a plastid organelle, 
harbors the machinery for FAS-II which is essential for the survival of T. gondii and for 
liver stage malaria parasites.  A small biocide, triclosan, is known to target the last 
enzyme in FAS-II with high specificity.  Several modifications were made to this scaffold 
molecule to increase its druggability properties, while retaining specificity.  We designed 
a method to measure the inhibition and IC50 values of triclosan analogues in 96-well plate 
format.  Also, we modified a thermal shift assay to measure their binding affinity to the 
enzyme and determine their inhibition mode of action.  The FAS-II produces octanoyl-
ACP, which is the substrate of downstream enzymes to synthesize lipoate on pyruvate 
dehydrogenase (PDH).  Contrary to the apicoplast, the mitochondrion relies on lipoate 
scavenged from the host which is essential for the survival of these parasites.  In both 
parasites, two lipoate ligases are localized to the mitochondrion, LipL1 and LipL2.  These 
ligases are believed to catalyze the attachment of lipoate to three lipoate-requiring 
substrates in the mitochondrion: the H-protein, the branch chain amino acid 
dehydrogenase (BCDH) and the α-ketoglutarate dehydrogenase (KDH).  We show that 
LipL1 is the sole lipoate ligase in the mitochondrion with specificity for the H-protein.  
The BCDH and KDH are lipoylated through a concerted mechanism: LipL1 produces the 
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conjugate lipoyl-AMP which is transferred to LipL2 to lipoylate the BCDH and KDH.  
LipL2 is unable to produce the lipoyl-AMP conjugate, but instead acts as a lipoyl-
AMP:N-lysine lipoyltransferase.   The two step LipL1+LipL2 lipoylation mechanism 
appears to be conserved in most apicomplexan parasites, since the genes encoding both 
enzymes are conserved.   Furthermore, lipoate scavenging shows redox sensitivity for the 
lipoate redox state -a phenomenon that has not been previously described-.  Last, we can 
target the mitochondrial proteins with lipoate analogues and inhibit their activities, 
causing cell growth inhibition.  The lipoylation mechanism found in apicomplexan 
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Introduction to lipoate 
Lipoate (Figure 1) is a highly conserved cofactor involved in several oxidative 
decarboxylation reactions and one carbon metabolism.1  This cofactor is a lipophilic 
molecule with acidic properties, and is involved in the anabolism of fatty acids.  Lipoate 
has a role in catalysis of multienzyme complexes, such as α-ketoacid dehydrogenases and 
the glycine cleavage system, involved in intermediate metabolism (Figure 2).1  These 
enzymes require lipoate to be attached to a conserved lysine of the lipoylation domain, 
forming an amide linkage.2, 3  This lipoamide acts as a swinging arm shuffling reaction 
intermediates between different active sites in the multienzyme complexes.  Additionally, 
due to the redox activity of lipoate, it can function as an antioxidant and free-radical 
scavenger.4, 5  Free living organisms employ different strategies to acquire lipoate 
including different mechanisms to scavenge or synthesize the cofactor.  For microbial 
pathogens, these strategies impact the virulence of these organisms and the pathogenesis 
of the diseases they cause.6  Here I review the function of lipoate in human pathogens 
with a focus on parasites belonging to the phylum Apicomplexa.  Specifically, we look at 
the mechanism of lipoate scavenging, and the function and specificity of the enzymes 
involved in scavenging pathways.   
 
Lipoate Function in Complexes 
To date, five lipoate requiring enzymes have been described.  Three are α-ketoacid 
deydrogenases: pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KDH) 
and branched chain amino acid α-ketoacid dehydrogenase (BCDH).6  These complexes 
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are composed of multiple copies of three subunits referred to as E1, E2 and E3 (Figure 
2).  A fourth complex, homologous to PDH, is the acetoin dehydrogenase which shares 
the general architecture of the α-ketoacid dehydrogenases.6  The fifth enzyme is the 
glycine cleavage system (GCV), which has a different architecture and is composed of 
four loosely associated proteins, called the P-, H-, T-, and L-proteins.6, 7  The GCV 
proteins are clearly related to those which form the α-ketoacid dehydrogenases in the 
sense that the P-protein is homologous to E1 proteins and the L-protein is homologous to 
E3 proteins.  The H-protein and T-protein are homologous to the lipoylation domains and 
catalytic domains of E2 proteins.  Lipoate is attached through an amide bond to a specific 
lysine in the lipoylation domain (LD).  LDs are typically found at the N-terminus of the 
E2 subunits and in the case of PDH E2 proteins, there can be up to three LDs in 
tandem.2,3   
The catalytic cycle of lipoate dependent enzymes begins with lipoamide (lipoate 
attached to the LD through an amide bond) in the oxidized or close ring form.  Lipoamide 
serves as the substrate for reductive acylation catalyzed by the E1 domain.  The catalytic 
cycle of PDH serves as a good example and is illustrated in Figure 2.  In the first step, 
the E1 domain uses its thiamine pyrophosphate cofactor to decarboxylate pyruvate 
followed by the transfer of the acetyl group to lipoamide on the E2 subunit.  The flexible 
lipoamide group is used to transfer the acetyl group to the catalytic domain of the E2 
subunit where it is transferred to coenzyme A.  After this step, lipoamide is found in the 
reduced or open ring form, dihydrolipoamide.  The flavin-dependent E3 subunit catalyzes 
the two-electron oxidation of dihydrolipoamide to lipoamide, forming NADH in the 
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process (Figure 2).6  The GCV works in a similar fashion where the P-protein acts as the 
E1 subunit catalyzing the decarboxylation of glycine and formation of aminomethylene-
lipoamide on the H-protein.  The T-protein catalyzes the transfer of the methylene group 
to tetrahydrofolate, forming 5,10-methylene-tetrahyrofolate and releasing ammonia.  The 
L-protein then acts as an E3 subunit catalyzing the oxidation of dihydrolipoamide to 
lipoamide.6   
These complexes are typically involved in central metabolism in one carbon 
metabolism.  The PDH complex catalyzes the oxidative decarboxylation of pyruvate to 
acetyl-CoA.  Acetyl-CoA feeds into the citric acid cycle (TCA), fatty acid biosynthesis 
and elongation, and mevalonate pathway of isoprenoid biosynthesis.6, 8  The KDH 
complex converts α-ketoglutarate to succinyl-CoA, which can be used in the TCA cycle 
or be diverted for heme and amino acid biosynthesis.9, 10  The BCDH complex functions 
as part of the degradation of branch chain amino acids.6  The branch chain amino acids 
have to be deaminated by the action of a transaminase.  The resulting α-ketoacids are the 
substrates of BCDH to generate branch-chain-CoA molecules that can be converted into 
intermediates of the TCA cycle or used for branch chain fatty acid synthesis.  The GCV 
system catalyzes the reversible decarboxylation of glycine.  During glycine catabolism, 
the GCV produces NADH, CO2, NH3 and the one-carbon donor molecule 5,10-
methylene-tetrahyrofolate, which is used for the biosynthesis of some amino acids and 
nucleotides.11 
 




There are two general pathways by which organisms can acquire lipoate: scavenging 
and biosynthesis (Figure 3).  The mechanisms for each pathway can differ from 
organism to organism.  Lipoate metabolism has been best characterized in Escherichia 
coli (E. coli), which contains both scavenging and synthesis pathways (Figures 3A and 
3C).12  When lipoate is present in the media, E. coli scavenges the cofactor and a 
dedicated lipoate ligase (EcLplA) catalyzes the attachment of lipoate to the different 
substrates through an ATP dependent reaction.  This enzyme proceeds through a two-step 
mechanism (Figure 4).13  First, lipoate is activated with ATP forming the intermediate 
conjugate lipoyl-AMP.  Second, the lipoyl moiety of the lipoyl-AMP conjugate is 
transferred to a conserved lysine of the apo-substrates.  The E. coli lipoate ligase has been 
crystallized and found to have two domains, a large N-terminal domain and a small C-
terminal domain (Figure 5).13  In the unliganded form, the ligase is found in a 
conformation where the C-terminal domain folds over the active site.  After the 
adenylation reaction, forming lipoyl-AMP, the C-terminal domain rotates relative to the 
N-terminal domain by about 180 degrees and the enzyme assumes a more linear stretched 
conformation.  The lipoyl-AMP conjugate assumes a U-shape conformation with the 
adenine base and the dithiolane ring buried while the linker region containing the 
phosphate and part of the ribose ring is exposed to solvent in the active site of the ligase.  
When the ligase is in the linear conformation, it can recognize and bind protein 
lipoylation substrates (Figure 5).13   Protein substrates are bound in a conformation that 
orients a specific lysine side chain towards the carbonyl carbon of the lipoyl moiety.  
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Subsequent attack by the amine of the lysine side chain breaks the phosphodiester bond 
of the conjugate, forming lipoylated protein and AMP.   
It is known that a conserved lysine in the active site of EcLplA forms hydrogen bonds 
with the oxygen of both the lipoyl moiety and the phosphate in lipoyl-AMP (Figure 6).13  
This residue has being shown to be essential for both the activation and transfer of 
lipoate.  Mutation of this lysine to alanine in the EcLplA resulted in almost complete 
abolishment of lipoylation in in vitro assays.13  The hydrogen bonds formed between the 
lysine and lipoyl-AMP make the phosphodiester bond more labile for the apo-substrate to 
attack this bond and become lipoylated (Figure 6).13   
Other organisms have been studied and found that the mechanism by which lipoate is 
acquired differs from E. coli.  An example of this is Thermoplasma acidophilum, which 
has two separate proteins that come together to catalyze the activation of lipoate.14, 15  
Interestingly, these lipoate ligases (TaLplA and TaLplB) correspond to the N-terminal 
and C-terminal domains found in E. coli, respectively.  T. acidophilum evolved to have 
both domains expressed on different genes.14, 15  The C-terminal domain in E. coli and the 
LplB protein in T. acidophilum are not catalytically active, but are required for the 
formation of lipoyl-AMP.  TaLplA (corresponding to the N-terminal domain in EcLpLA) 
is sufficient to catalyze the transfer reaction without the presence of TaLplB if it is 
supplied with lipoyl-AMP.14-16  
Another bacterium that has been studied for lipoate scavenging is Chlamydia 
trachomatis (Ct).17  Ct is an obligate intracellular pathogen causative of sexually 
transmitted disease Chlamydia.18  This bacterium presents an interesting scenario for 
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lipoate metabolism, which resembles what happens in the mitochondrion of Apicomplexa 
pararites (see below).17  Ct encodes one gene for lipoate biosynthesis, the lipoyl synthase 
(CtLipA) with 47% sequence identity to EcLipA.  However, CtLipA could not 
complement a lipoylation deficient cell line where EcLplA and EcLipA were knocked 
out, making it difficult to assign its function.17  C. trachomatis does encode enzymes 
believed to be responsible for lipoate scavenging.  Contrary to E. coli, which contains 
only one lipoate ligase, Ct contains two lipoate ligases: CtLplA1 and CtLplA2, with 30% 
and 27% sequence identity to EcLplA, respectively.    Furthermore, Ct contains four 
lipoylation substrates: the PDH, KDH, BCDH and the H-protein.  Interestingly, no 
identifiable components of the GCV have been found in the Ct genome except for the H-
protein.19  Overall, this scenario is similar scenario to what we observe in Plasmodium 
spp. and other Apicomplexa which also contain two potential lipoate ligases and an 
incomplete GCV.  Thus far, only CtLplA1 has been shown to have lipoate ligase activity 
capable of complementing a lipoylation deficient E. coli cell line.  It also lipoylates the 
CtBCDH in vitro in an ATP-dependent reaction.  No activity has been detected for 
CtLplA2; it cannot complement the lipoylation deficient E. coli cell line or lipoylate the 
CtBCDH in an in vitro reaction.17 
 
Lipoate Biosynthesis 
An alternative to lipoate scavenging is synthesis of the cofactor.  Lipoate synthesis 
typically proceeds through the sequential action of two separate enzymes (Figure 3C).  
First, an octanoyl transferase (EcLipB) transfers the octanoyl moiety from octanoyl-Acyl 
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Carrier Protein (octanoyl-ACP) to the conserved lysine of the protein substrates.20  A 
second enzyme, a lipoyl synthase (EcLipA), inserts two sulfur atoms at carbon 6 and 8 to 
yield the R-enantiomer, which is the biologically active form.21  This pathway is well 
conserved throughout kingdoms, with two known variations on this theme.  One 
exception is Bacillus subtilis (Figure 3B),22, 23 in which a dedicated octanoyl transferase 
(BsLipM) transfers the octanoyl moiety from octanoyl-ACP specifically to the H-protein.  
A second enzyme (BsLipM) is needed to shuffle the octanoyl moiety from the H-protein 
to other protein substrates.22, 23  Lastly, a lipoyl synthase (BsLipA) catalyzes the sulfur 
insertion reaction to generate lipoylated proteins.22, 23   
 
Eukaryotic Lipoate Metabolism 
Fungal Lipoate Biosynthesis 
Another known pathway for lipoate biosynthesis is found in Saccharomyces 
cerevisiae,24, 25 in which an octanoyl transferase (ScLip2) transfers the octanoyl moiety 
from octanoyl-ACP specifically to the H-protein.24, 25  A second route has been proposed 
in S. cerevisiae, in which octanoyl-ACP is converted to octanoyl-CoA through the action 
of an acyl-ACP:CoA transferase.  Octanoyl-CoA is the substrate of another octanoyl 
transferase (ScLip3) to lipoylate the PDH and KDH in the mitochondria of the fungus.25  
Then, a lipoyl synthase (ScLip5) inserts two sulfurs to generate lipoylated substrates for 
both routes of lipoylation.  One possibility, not explored in recent publication, is that 
ScLip5 could use octanoyl-ACP as substrate rendering the acyl-ACP:CoA transferase 
activity redundant.  A previous report suggested the need for all four proteins (ScLip2, 
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ScLip3, ScLip5 and H-protein) to remain in a complex to lipoylate the PDH and KDH.24  
Also, the proposed activity of ScLip5 was to transfer the octanoyl moiety from octanoyl-
H-protein, similar to what was observed in B. subtilis.  These possibilities were not 
explored in a subsequent publication.25  Thus, the physiologically relevant lipoylation 
routes in Sc remain unclear. 
 
Mammalian Lipoate Metabolism 
Most of the work done to understand mammalian lipoate metabolism has been done in 
Bos taurus (Bt) (Figure 3D), but homologous enzymes have been identified in humans.13, 
26-30 Lipoate metabolism starts with the scavenging of free lipoate.  Lipoate is activated 
preferentially with GTP, a difference to other systems, by a lipoate activating enzyme 
(LAE). 29 This LAE was identified to be a medium acyl-CoA synthase with no homology 
to any described lipoate ligase.  The function of this enzyme is to generate lipoyl-GMP, 
which is taken by an N-lysine lipoyltransferase (BtLipT) to lipoylate the different 
substrates.26-28, 30  The BtLipT enzyme is closely related to EcLplA, but it cannot catalyze 
the ligation reaction alone, and it relies on the activity of LAE to supply lipoyl-GMP.  
BtLipT has been crystallized in the presence and absence of lipoyl-AMP in the active 
site.13, 26  Interestingly, both structures were found in the stretched conformation that was 
observed for the EcLplA/lipoyl-AMP binary complex (refer to Figure 5).  Since the 
stretched conformation is thought to allow protein substrate binding, this may be an 
indication that BtLipT is poised to recruit protein substrates regardless of whether  lipoyl-
GMP is bound.  The bovine lipoylation mechanism is presumably shared by humans and 
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differs significantly from other described systems including those found in apicomplexan 
parasites (see below). 
 
Lipoate Metabolism in Apicomplexa 
Introduction to the phylum Apicomplexa 
The phylum Apicomplexa is comprised of protozoans that are exclusively the 
intracellular parasites of animals.6  These protozoans, with some exceptions, contain two 
endosymbiont organelles: the mitochondrion and the apicoplast.  These organelles harbor 
lipoate scavenging and biosynthesis pathways, respectively.6, 31-33  The apicoplast is a 
non-photosynthetic organelle that resulted from the secondary endosymbiosis of a red 
algae that had previously incorporated a cyanobacterium.34  As a result, the apicoplast 
harbors prokaryotic-like metabolic pathways that differ from human pathways, making it 
an attractive drug target.34, 35   
Lipoate metabolism and/or downstream pathways are essential for survival of some 
parasites in this phylum, two of which are Plasmodium spp. and Toxoplasma gondii (T. 
gondii).  Five Plasmodium spp. have been identified to cause malaria in humans: P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi.36-39  Plasmodium falciparum 
(Pf) is the deadliest parasite, causing over 1 million deaths annually, primarily affecting 
children under the age of 5 and pregnant women in sub-Saharan Africa and Southeast 
Asia.36-39  T. gondii causes toxoplasmosis in humans and infects about one third of the 





Life cycle of Apicomplexan parasites 
Plasmodium spp. have a life cycle comprised of three stages: a sexual stage in the 
mosquito which serves as the vector for transmission; and two distinct asexual stages in 
the human host comprised of liver infection followed by the blood stage cycle.  After 
transmission from the mosquito vector, malaria parasites exclusively infect a relatively 
small (<100) number of liver cells.  Over the course of several days, they undergo rapid 
replication ultimately producing several thousand parasites per infected hepatocyte.  
These parasites leave the liver and infect erythrocytes beginning the blood stage cycle of 
the disease.  Depending on the species, malaria parasites infect and replicate in red blood 
cells over the course of 1-2 days.  When replication is complete, the erythrocyte ruptures 
releasing between one and two dozen parasites capable of infecting more erythrocytes.  It 
is the synchronous rupture of erythrocytes during the red blood cell cycle of malaria 
which causes the debilitating periodic fevers that are the hallmark symptoms of the 
disease.  The World Health Organizations recommends Artemisinin Combination 
Therapy (ACT) as a treatment of malaria, but treatment failure has been reported in some 
regions.  Increasing drug resistant to current drugs makes it necessary to exploit essential 
pathways for drug development.46-48  Drugs targeting the liver stage serve as prophylactic 
drugs preventing disease, whereas blood stage drugs serve as a treatment of the disease.  
One pathway that could serve as a target for both liver and blood stages is lipoate 
metabolism.31, 35   
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The T. gondii life cycle is comprised of a sexual phase that only takes place in the 
primary host (cats of the Felidae family), and an asexual phase that can occur in any 
warm-blooded animal, including humans.49, 50  There is no available vaccine to prevent 
infection in humans.  The only available treatments are the antifolate medicines 
sulfadiazine and pyrimethamine.42, 44  These medications are effective against 
tachyzoites, the obligate intracellular form of the parasite in the acute stage of the disease, 
but they are ineffective against the encysted, latent bradyzoites.51   
 
Lipoate in Plasmodium spp. 
Lipoate metabolism has been described in Plasmodium falciparum (Pf) and 
Plasmodium berghei.  Plasmodium spp. have been shown to have both synthesis and 
scavenging pathways (Figure 7).31-33, 52  These pathways are non-redundant and are 
found in separate compartments.  The parasite mitochondrion relies on lipoate scavenged 
from the host.  This was shown by treating Pf parasites with radiolabeled lipoate (35S-
lipoate), where only mitochondrial substrates were modified.31  Treatment Pf parasites 
with a lipoate analog, 8-bromooctanoate (8-BrO), caused cell death with a MIC50 of 
about 400 µM and resulted in dose-dependent reduced lipoylation of the mitochondrial 
substrates.  These results suggested that lipoate scavenging is essential for blood stage 
parasite growth.31   
Once lipoate is imported into the mitochondrion there are two candidate lipoate ligases, 
lipoate ligase 1 (LipL1) and lipoate ligase 2 (LipL2), that could catalyze the attachment 
of this cofactor to the lipoate requiring substrates through an ATP dependent reaction 
13 
 
(Figure 7).31, 52, 53  Three possible substrates have been shown or predicted to be in the 
mitochondrion: the H protein of the GCV and the E2 subunits of the BCDH and KDH.7, 32  
It has been shown that LipL1 can complement a lipoylation deficient E. coli cell line, 
confirming its activity as a ligase.  Also, recombinant LipL1 can lipoylate the H-protein 
in an in vitro lipoylation reaction that requires ATP.31  Presumably, this activity is 
analogous to the ATP-dependent lipoate ligase reaction catalyzed by EcLplA.  No 
activity is known for P. falciparum LipL2.  It can partially complement a lipoylation 
deficient E. coli cell line, however, only partial growth was observed after four days of 
incubation, suggesting that it is a poor lipoate ligase.31  As mentioned earlier, 
mitochondrial lipoate metabolism in Plasmodium spp. appears to be similar to what is 
observed in C. trachomatis.  Interestingly, both identified lipoate ligase 2 (LipL2 in Pf 
and LplA2 in Ct) are more closely related to each other than to their lipoate ligase 1 
counterparts.  It would be interesting to determine if both share similar activities and 
conservation spanning the bacteria and protist kingdoms. 
The lipoate synthesis machinery is exclusively localized to the apicoplast.54, 55  The 
synthesis pathway in Plasmodium spp. follows the same steps as the one described for E. 
coli.  Recent studies have shown that many apicoplast pathways are dispensable in the 
blood stage of malaria parasites.54, 55  The apicoplast contains a single lipoate requiring 
protein, the pyruvate dehydrogenase (PDH).54  This enzyme is responsible for the 
generation of acetyl-CoA, which feeds into the Fatty Acid Synthesis Type II pathway 
(FAS-II).  The FAS-II pathway is dispensable for blood stage parasite growth, but it is 
essential for liver stage development and for progression from liver to blood stage.54  The 
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PDH activity has also been shown to be essential for liver stage parasite development, 
making it a candidate target for malaria chemoprophylaxis.   
Plasmodium berghei (P. berghei) is a rodent malaria parasite and cannot infect humans.  
However, P. berghei is well studied because it serves as a model system to study liver 
stage infection (in mice) which is much more difficult to do with human malaria parasite 
species.   P. berghei contains both lipoate scavenging and biosynthesis pathways 
localized to the mitochondrion and apicoplast, respectively.55  Similar to P. falciparum, 
treatment of P. berghei parasites with 8-BrO resulted in abolished lipoylation of 
mitochondrial substrates, but not of the apicoplast substrate, PDH.  8-BrO also resulted in 
reduced ability of the parasites to successfully complete liver stage development.55  
Furthermore, knockout of the LipB enzyme in the apicoplast resulted in sporozoites that 
are markedly attenuated in their infectivity for mice and arrest in very late liver stage.55  
Together, these results show the importance of lipoate metabolism for parasite 
development in both liver and blood stages. 
 
Lipoate in Toxoplasma gondii 
T. gondii also contains the biosynthesis and scavenging machinery which localize to 
the apicoplast and the mitochondrion, respectively (Figure 7).56-58  As in Plasmodium 
spp., T. gondii relies on lipoate scavenged from the host and contains two lipoate ligase 
candidates, as well as the same lipoate requiring substrates in the mitochondrion.58  It is 
likely that these enzymes share the same functions as in malaria parasites, since these 
organisms are very similar.  Treatment of T. gondii parasites with 8-BrO also resulted in 
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growth inhibition, presumably due to inhibition of key lipoate-dependent proteins in the 
mitochondrion.58   Apicoplast metabolism appears to have elevated significance in T. 
gondii compared to Plasmodium spp.  The only substrate is also the PDH and the lipoate 
synthesis machinery functions the same way as for Plasmodium.57  The role of the PDH 
in the apicoplast is also to supply acetyl-CoA to the FAS-II pathway.  Contrary to results 
observed for erythrocytic stage P. falciparum, in T. gondii the lipoate biosynthesis 
machinery, PDH activity, and the FAS-II pathway are essential for parasite survival 
(Figure 8).56   
 
Fatty Acid Synthesis Type II (FAS-II) 
Because of the essentiality of the FAS-II pathway in T. gondii, and the fact that these 
enzymes do not exist in humans, this pathway has been exploited for drug discovery.  
Humans have a FAS type I pathway which consist of a single polypeptide with multiple 
enzymatic domains.59  The FAS-II elongation pathway consists of four separate enzymes 
that follow an iterative process beginning with the condensation of malonyl-CoA to the 
nascent fatty acid bound to ACP (Figure 8).60  The condensation step is followed by 
reduction, dehydration and a final reduction step.  The last enzyme in FAS-II is the Enoyl 
ACP Reductase (ENR), which is the rate-limiting step and is responsible for the final 
reductive step in each round of the fatty acid chain elongation, the NADH-dependent 
reduction of trans-2-enoyl-ACP to acyl-ACP.60  This enzyme has been well studied and is 
the target of some antiparasitic and antibacterial compounds including diazaborines, 
isoniazid and triclosan.61-63  Triclosan is a very potent inhibitor of TgENR with IC50 
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values around 20 nM and MIC50 around 200 nM for T. gondii in culture.64  Even though 
triclosan is a potent inhibitor, it is not suitable as a drug due to its poor solubility and 
drug like properties.  As a result, triclosan has served as a scaffold molecule to increase 
its solubility and make it a more suitable drug.65, 66   
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Figure 1 – Different forms of the cofactor 1,2-dithiolane-3-pentanoic acid.  A)  Lipoic 
acid (protonated form).  B)  Lipoate (deprotonated) which is the form found in solution at 




Figure 2 – Pyruvate Dehydrogenase (PDH) Complex.  PDH is one of five complexes that 
require lipoate for its function.  PDH is composed of three subunits named: E1, E2 and 
E3.  The E1 subunit catalyzes the decarboxylation of pyruvate using its thiamine 
pyrophosphate cofactor.  The E2 subunit is composed of an N-terminal lipoyl domain and 
C-terminal catalytic domain.  The E1 domain then catalyzes the reductive acetylation of 
the lipoamide on the E2 lipoyl domain.  The acetyl-lipoamide product is then shuttled 
from the E1 subunit to the E2 catalytic domain where the acetyl group is transferred to 
coenzyme A (CoA) forming acetyl-CoA.  The E3 subunit oxidizes the reduced form of 
lipoamide, dihydrolipoamide, in a NAD
+
 dependent reaction and the catalytic cycle can 














Figure 3 – Different lipoate metabolic pathways.  A)  In E. coli, lipoate synthesis starts 
by transferring the octanoyl moiety from octanoyl-ACP to the different lipoate requiring 
substrates (E2 proteins) by the action of an octanoyl transferase (EcLipB).  A second 
enzyme, lipoyl synthase (EcLipA), inserts two sulfurs atoms at carbon 6 and 8 to generate 
the lipoyl-substrates.  B)  B. subtilis lipoate synthesis also starts with the action of an 
octanoyl transferase (BsLipM), but with specificity for only the H-protein.  A second 
enzyme, BsLipL, shuffles the octanoyl moiety to the other substrates.  Last, a lipoyl 
synthase (BsLipA) generates the lipoyl moiety similar to E. coli.  C)  E. coli also has a 
scavenging pathway in which a dedicated lipoate ligase (EcLplA) takes free lipoate and 
activates it with ATP, generating lipoyl-AMP, and then transferring the lipoyl moiety to 
the protein substrates.   D) In mammalian organisms lipoate is activated by a lipoate 
activating enzyme, a medium acyl-CoA synthase, through a GTP dependant reaction.  
The formed conjugate, lipoyl-GMP is the substrate for an N-lysine lipoyltransferase to 






Figure 4 – Typical mechanism of lipoate ligases.  A)  The first step is an adenylation 
reaction, in which lipoate is activated with ATP, generating the lipoyl-AMP conjugate.  
B)  The lipoyl moiety from the conjugate is then transferred to a specific lysine of the 
different lipoate requiring substrates. 
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Figure 5 – Lipoate ligases architecture.  Lipoate ligases have two domains: a large N-
terminal domain and a small C-terminal domain.  The active site is found in the N-
terminal domain where the lipoate, ATP and lipoyl-AMP are bound.  In the unliganded 
form, the C-terminal adopts a bent conformation.  Upon activation of lipoate, lipoyl-AMP 
formation, three conformational changes occur:  1) an adenylate binding loop becomes 
ordered protecting the AMP portion of lipoyl-AMP;  2) a second loop, called the lipoyl 
binding loop, folds over the lipoyl moiety;  and 3) the C-terminal domain rotates relative 
to the N-terminal domain adopting a more linear conformation.  This stretched 
conformation is how the enzyme recognizes the apo-substrate proteins.  The ε-amino 
group of the lysine of apo-substrates is positioned to attack to the carbonyl group of the 
lipoyl-AMP.  After the transfer reaction is completed, the ligase assumes the relaxed or 




Figure 6 – Conserved lysine is essential for overall ligase activity.  It has been shown for 
EcLplA that a conserved lysine (K133) assembles the ATP and lipoate in the active site, 
forming hydrogen bonds with the carboxyl group of lipoate and the ribose and phosphate 
of ATP (not shown).  This facilitates the nucleophilic attack of the carboxyl group of 
lipoate on the α-phosphorous atom of ATP, forming lipoyl-AMP.  Upon formation of 
lipoyl-AMP, the conjugate assumes a U-shaped conformation in the active site.  The 
K133 remains hydrogen bonded with the carbonyl group and ribose moiety of lipoyl-
AMP, helping to orient the conjugate in the active site.  K133 also facilitates nucleophilic 





Figure 7 – Lipoate metabolism of Plasmodium spp. and Toxoplasma gondii.  Both 
parasites contain lipoate scavenging and synthesis pathways.  These pathways are 
localized in distinct organelles and have been shown to be non-redundant.   The 
mitochondrion relies on lipoate scavenged from the host involving the import of lipoate 
and its attachment to the different apo-substrates in an ATP dependent reaction by a 
lipoate ligase (LipL1 and/or LipL2).  The apicoplast relies on lipoate synthesis for the 
sole substrate, pyruvate dehydrogenase (PDH).  Lipoate is synthesized on the PDH by the 
action of two enzymes, octanoyl transferase (LipB) and lipoyl synthase (LipA).  Lipoyl-





Figure 8 – Fatty Acid Synthesis Type II (FAS-II).  The FAS-II pathway is located in the 
apicoplast organelle and is essential for Toxoplasma gondii survival.  FAS-II starts with 
the condensation of malonyl-CoA to a nascent acyl-ACP chain in an iterative process 
involving four separate enzymes.  The last and rate-limiting step is catalyzed by FabI or 
Enoyl Acyl-Carrier Protein (ACP) Reductase (ENR).  This enzyme is the target of 















Toxoplasma gondii Enoyl-Acyl Carrier Protein Inhibition Assay 
 
The methods described in this chapter were used to generate data for the 
following publications: 
Antimicrob. Agents Chemother., 56, 266-2682 (2012). 
ChemMedChem, 8, 442-461 (2013). 
Bioorg. Med. Chem. Lett., 23, 2035-2043 (2013). 
Bioorg. Med. Chem. Lett., 23, 3551-3555 (2013). 
ChemMedChem, 8, 1138-1160 (2013). 





Toxoplasma gondii (T. gondii) is a protozoan parasite that belongs to the phylum 
Apicomplexa.1-3  T. gondii contains a plastid organelle called the apicoplast that harbors 
plant-like pathways that differ from human pathways.4-6  Several medicinal studies are 
looking for essential pathways that can serve as drug targets.7-9  One such pathway is the 
Fatty Acid Synthesis type II (FAS-II) found in the apicoplast of T. gondii.10 Contrary to 
the type II pathway found in T. gondii, humans rely on a type I pathway which is encoded 
in a single polypeptide chain.  The biosynthesis of fatty acids is an iterative process 
starting with the condensation of malonyl-CoA to a nascent fatty acid chain that is 
covalently bound to the Acyl Carrier Protein (ACP).  A total of four enzymes are found 
in FAS-II pathways, with the final reductive step in each round of fatty acid elongation 
catalyzed by the Enoyl-ACP Reductase (ENR).  ENR catalyzes the NADH-dependent 
reduction of trans-2-enoyl-ACP to acyl-ACP.9, 10  The T. gondii ENR (TgENR) protein 
has been studied and found to be essential for parasite survival.9    
Many inhibitors of bacterial and parasitic ENR enzymes have been previously 
described including diazaborines, isoniazid and triclosan (Table 1).9, 11  Triclosan is a 
very potent inhibitor of the TgENR enzyme with a low nanomolar IC50 value; it also 
inhibits parasite growth in the low micromolar range.  Regardless of its potency, triclosan 
is unsuitable for oral administration due to its poor pharmacokinetic properties, especially 
low solubility.  Triclosan has served as a scaffold molecule in medicinal chemistry 
studies focused on increasing its solubility and improving the Absorption, Distribution, 
Metabolism, Excretion and Toxicity (ADMET) properties.7, 8  As part of a collaborative 
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effort focused on TgENR as a drug target, we developed a medium-throughput assay to 
assess potential inhibitors.  Although trans-2-enoyl-ACP species are the physiological 
substrates for TgENR, the enzyme will catalyze the reduction of trans-2-enoyl-Coenzyme 
A species as well.  We used trans-2-butyryl-Coenzyme A (crotonyl-CoA) since it is the 
cheapest ENR substrate commercially available.  Using this substrate, we developed a 
kinetic assay of TgENR activity based on monitoring the absorbance of the NADH 
cofactor as it is consumed over the course of the reaction.  We adapted this assay to 
function in 96-well plate format and ultimately assessed the activity of ~8,000 
compounds.   
We first expressed and purified recombinant TgENR as described previously.12  An 
assay of TgENR enzymatic activity used previously13 was adapted for use in 96-well 
plates.  The activity of TgENR was monitored by consumption of NADH at a wavelength 
of 340 nm with an extinction coefficient of 6220 M-1cm-1.  We monitored the NADH 
consumption throughout the experiment using a SpectraMax M2 plate reader.  This 
machine measures the absorption in each well of the plate every 35 seconds for a total of 
15 minutes.  Each well contained a reaction with a final volume of 100 µL in 96-well 
Corning UV plates.  Each well contained a final concentration of 100 µM Crotonyl-CoA 
(Sigma), 100 µM NADH, 5 nM of TgENR and 1% DMSO.  Initial screening was done 
with potential inhibitors (dissolved in DMSO) at a final concentration of 1 µM.  Dilution 
series were subsequently used to determine IC50 values for successful inhibitors. 
 




1. 1mM Crotonyl-CoA:  Stock solutions of 10 mM Crotonyl-CoA (in water) were 
stored at -80 degrees in aliquots of 100 µL.  A total of 900 µL of dH2O was added 
to an aliquot immediately prior to use bringing it to the 1 mM working 
concentration.   
2. Crotonyl-CoA plate:  A total of 83 µL of 1 mM of Crotonyl-CoA were pipetted 
into each well of the first row of a V-bottom plate (Costar 3896) to serve as the 
source material for a 96-well assay plate.   
3. Drug plate:   
a. In a different V-bottom plate, 20 µL of DMSO was added to each of the 
eight wells in the first column of the plate to serve as baseline controls. 
b. In columns 2-11, 20 µL of 100 µM compound diluted in DMSO (Sigma) 
were added to each well. 
c. The eight wells in column 12 contained a dilution series of the inhibitor 
triclosan (in DMSO) starting with 10 µM and ending with 610 pM 
(dilutions by factors of 4). 
4. TgENR enzyme:  The TgENR was stored in 10 µL aliquots at a concentration of 
0.5 mg/mL at -80 degrees for single use to avoid freeze/thaw cycles.  Thawed 
enzyme was stored on ice.  
5. 1 mM NADH:  Aliquots of 120 µL of 10 mM NADH stock solution were stored 
at -80 degrees for single use.  This material must be used fairly soon after thawing 
since NADH oxidizes in solutions exposed to air.  A total of 1080 µL of dH2O 
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was added to this aliquot to generate the 1mM NADH working solution which 
was kept on ice.  
 
Assay plate preparation 
1. A 12-well multichannel pipette was used to transfer 10 µL of 1 mM Crotonyl-
CoA from the first row of the Crotonyl-CoA plate to each row of a UV-plate 
(Sigma).     
2. Using a 12-well multichannel pipette, a total of 1 µL of each drug was transferred 
from the drug plate to the UV-plate row by row.  Each row was pipetted twice to 
run the samples in duplicates at a final concentration of 1 µM.  It was important at 
this step to make sure that bubbles are not formed while pipetting the drugs. 
3. The reaction buffer (9.5 mL of 127 mM Phosphate, 190 mM NaCl, pH 7.5) was 
then mixed with 1.2 mL of 1 mM NADH and 4 µL of 0.5 mg/mL TgENR  in a 15 
mL conical tube.  This reaction mixture was then transferred to a v-bottom 
reservoir. 
4. Then a total of 89 µL of reaction mixture was added to the assay plate to yield a 
final concentration of 5nM TgENR, 100 mM Na/K Phosphate and 150 mM NaCl 
buffer pH 7.5 and 100 µM NADH.  The reaction mixture was added row by row 
(with a brief with pipetting up and down) with a 12-channel pipettor to initiate the 
assay.  The assay plate was then loaded on the SpectraMax M2 plate reader and 




Plate reader and assay 
1. The SpectraMax plate reader measures the absorption at 340 nm for 15 minutes 
with measurements being made for each well in the 96-well plate every 35 
seconds.  The slopes were calculated by the program in the SpectraMax M2, and 
analyzed using Excel.  Because we were monitoring the NADH consumption, the 
slopes had a negative value.  In general, using the time frame of 50-200 seconds 
to calculate the slopes was ideal for the amount of enzymatic activity that we 
observed.   
2. The first column of each plate contained blank reactions with 1% DMSO which 
served as baseline activities for each row of the assay plate.   
3. The last column of each plate contained the potent inhibitor triclosan which 
served as a positive control for TgENR inhibition.   
4. The enzymatic activity was determined by comparing the slopes of the 
absorbance curves for each drug (mdrug) to those of the baselines (mblank) in the 
first column of the plate.   
5. The percent of inhibition was calculated using the following equation.  Each 
compound was screened in duplicates in the same assay at 1 µM final 
concentration. 
% inhibition at 1 µM = ( 100  
To determine the reproducibility and quality of the assay, we calculated the Z-factor.  
The Z-factor14 is a statistic value that describes the quality of the assay, with values 





|µ  µ |
 
Where σs is the standard deviation of the sample, σc is the standard deviation of the 
control, µs is the mean of the library sample and µc is the mean of the library control.  For 
the assay previously described, the Z-value was calculated from positive and negative 
control data spanning 25 plates and was found to be 0.65.  
As mentioned previously, all compounds were initially screened in duplicate at a 
concentration of 1 µM.  The compounds with significant inhibition, >90%, were further 
analyzed to determine their IC50 values.  The IC50 values were determined in triplicate 
with each replicate consisting of 11 inhibitor concentrations ranging from 10 µM to 170 
pM (serial dilutions by factors of 3), following the same protocol as described above.  
After obtaining the percent of inhibition for each concentration, a nonlinear regression 
analysis was performed using GraphPad Prism software.   The output of GraphPad Prism 
gives the IC50 value as well as a 95% confidence interval for each measurement.  The 
table below was modified from different publications, which include the compound 
synthesis and other biological tests.7, 8, 15, 16 
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Discrimination of Potent Inhibitors of Toxoplasma gondii Enoyl-Acyl Carrier 
Protein Reductase by a Thermal Shift Assay 
 













Many microbial pathogens rely on a Fatty Acid Synthesis Type II (FAS-II) pathway 
which is distinct from the type I pathway found in humans.  Enoyl-Acyl Carrier Protein 
Reductase (ENR) is an essential FAS-II pathway enzyme and the target of a number of 
antimicrobial drug discovery efforts.  The biocide triclosan is established as a potent 
inhibitor of ENR and has been the starting point for medicinal chemistry studies.  We 
evaluated a series of triclosan analogs for their ability to inhibit the growth of 
Toxoplasma gondii, a pervasive human pathogen, and its ENR enzyme (TgENR).  
Several compounds were identified that inhibited TgENR at low nanomolar 
concentrations, but could not be further differentiated due to the limited dynamic range of 
the TgENR activity assay.  Thus, we adapted a thermal shift assay (TSA) to directly 
measure the dissociation constant (Kd) of the most potent inhibitors identified in this 
study as well as inhibitors from previous studies.  Furthermore, the TSA allowed us to 
determine the mode of action of these compounds in the presence of NADH or NAD+ 
cofactors. We found that all of the inhibitors bind to a TgENR/NAD+ complex, but that 
they differed in their dependence on NAD+ concentration.  Ultimately, we were able to 
identify compounds which bind to the TgENR/NAD+ complex in the low femtomolar 
range. This shows how TSA data combined with enzyme inhibition, parasite growth 
inhibition data and ADMET predictions allow for better discrimination between potent 





Toxoplasma gondii is an obligate intracellular, protozoan parasite that infects about 
one third of the world’s population, causing substantial morbidity and mortality.1-6 The 
life cycle of T. gondii is comprised of a sexual phase that only takes place in the primary 
host (cats of the Felidae family), and an asexual phase that can occur in any warm-
blooded animal, including humans.7, 8  Currently there is no available vaccine to prevent 
infection in humans, and only the antifolate medicines sulfadiazine and pyrimethamine 
are typically used for treatment of T. gondii in humans.2, 9  Sulfonamides are associated 
with hypersensitivity, and pyrimethamine with bone marrow toxicity.  Even though these 
medications are effective against tachyzoites, the obligate intracellular form of the 
parasite in the acute stage of the disease, they are ineffective against the encysted, latent 
bradyzoites.  There is no available treatment to eliminate bradyzoites in humans.10 T. 
gondii infection in immunocompetent individuals is generally asymptomatic and self-
limiting, whereas in immunocompromised people, T. gondii infection can cause eye and 
brain disease such as toxoplasmic encephalitis, chorioretinitis and in severe cases can be 
fatal.11, 12  Pregnant women are especially at risk because the parasite can be transmitted 
from mother to fetus, and can lead to congenital toxoplasmosis that may result in 
abortion, neonatal death, or fetal abnormalities.2, 9, 13-18  
T. gondii parasites contain a plastid organelle, called the apicoplast, which harbors 
plant-like metabolic pathways.19  One pathway that resides in the apicoplast is the 
machinery for a Fatty Acid Synthesis Type II (FAS-II) pathway which is prokaryotic-
like.20, 21  The FAS-II pathway in T. gondii has been shown to be essential for parasite 
survival making it an attractive target for drug discovery efforts.22-26 In malaria parasites, 
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a similar FAS-II pathway is critical for liver stage development27, 28 and is thought to 
have an important role in the synthesis of lipoic acid.29  In contrast to the type II pathway, 
humans rely on a distinct type I pathway for bulk fatty acid synthesis, which is encoded 
in a single polypeptide chain.30  Fatty acid biosynthesis is an iterative process involving 
the condensation of malonyl-CoA with a nascent fatty acid chain that is covalently bound 
to Acyl Carrier Protein (ACP).  The enzyme Enoyl-ACP Reductase (ENR) is responsible 
for the final reductive step in each round of fatty acid chain elongation, the NADH-
dependent reduction of trans-2-enoyl-ACP to acyl-ACP.31  Many inhibitors of bacterial 
and parasitic ENR enzymes have been previously described including diazaborines, 
isoniazid and triclosan.32-34  It has been shown that triclosan inhibits TgENR with an IC50 
value of less than 20 nM in an in vitro inhibition assay using pure recombinant TgENR.35  
Triclosan also inhibits growth of T. gondii parasites with an IC50 of about 200 nM, 
presumably due to its inhibition of the FAS-II pathway.23 
Even though triclosan is a potent inhibitor of TgENR, it has limitations including poor 
bioavailability and impairment of muscle contractility that prevent it from being a safe 
and effective medicine.36  Instead, triclosan has been exploited as a scaffold to generate a 
series of analogues, many of which are also potent inhibitors of TgENR.35, 37-39  In this 
study, we report the inhibitory properties of a set of 2'-, 4'-, 5- and 6-substituted triclosan 
analogues developed as inhibitors of Plasmodium falciparum ENR (PfENR) and 
Mycobacterium tuberculosis ENR (MtInhA).27, 40-43  Several of these compounds 
inhibited TgENR at low nanomolar concentrations, the lowest concentrations that we are 
able to assess in our enzymatic activity assay.  To further characterize the inhibitory 
properties of these compounds and potent inhibitors from previous medicinal chemistry 
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efforts37, 39 we employed a thermal shift assay (TSA).  Using this assay, we were able to 
confirm the mode of action for all of the compounds as binding to the TgENR/NAD+ 
complex rather than to the TgENR/NADH complex or to TgENR alone.  Combined with 
thermodynamic parameters determined by differential scanning calorimetry, we 
calculated dissociation constants44-46 for NAD+ and NADH binding to TgENR as well as 
for inhibitor binding to the TgENR/NAD+ complex.  The Kd values we determined range 
from 6 mM (for NAD+ binding to TgENR) to 6.3 fM (for compound 19 binding to the 
TgENR/NAD+ complex), highlighting the large dynamic range of the TSA.  
Consequently, TSA results combined with enzyme and parasite inhibition data provide a 
better basis to differentiate between potent ENR inhibitors.   
 
Materials and Methods 
Compound Preparation and Synthesis 
Compounds were designed and synthesized as described by Alan Kozikowski 37, 39 and 
Jacobus Pharmaceutical Inc.27, 40-43  The purity of compounds 1-4,43 5-10,40 11-14,41, 42 
15-18,27 19-29,39 and 30-3237 was >95% as determined by HPLC and  the identity of each 
compound was verified by high resolution mass spectrometry.  The compounds were 
initially dissolved in DMSO at a concentration of 10 mM, and further diluted to required 
concentrations in culture media (described below).  For cell proliferation assays the final 
concentration of DMSO was not more than 0.1%, whereas for the in vitro TgENR 
enzyme assay the DMSO concentration was 1%. 
Parasite and Cell Culture 
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The strain of T. gondii parasites used in this set of experiments was a modified type I 
RH strain which expresses yellow florescent protein (RH-YFP), kindly provided by Dr. 
Boris Striepen (University of Georgia). Parasites were maintained in confluent 
monolayers of Human Foreskin Fibroblast (HFF) cells at 37 °C and 5% CO2 in culture 
medium consisting of Iscove’s Modified Dulbecco’s Medium supplemented with 10% 
Fetal Calf Serum, 1% Glutamax, and 1% Penicillin-Streptomycin-Fungizone 
(Invitrogen).  
 
In vitro Challenge Assay 
Growth inhibition of T. gondii was assessed as previously described.39 Host cells 
containing RH-YFP parasites were lysed by double passage through a 25g needle, and 
separated from the parasites by filtration and centrifugation. Confluent monolayers of 
HFF cells in 96-well plates (Falcon 96 Optilux Flat-bottom) were infected with 3,500 
parasites per well. Parasites were allowed to infect host cells for one hour, after which 
experimental compounds and control solutions were added. Seventy-two hours later, the 
parasite burden was assessed by measuring relative fluorescence using a Synergy H4 
Hybrid Reader (BioTek) and Gen5 1.10 software. All compounds and control solutions 
were tested in triplicate exemplars. Biological replicates of each experiment were 
performed twice for compound 17 and three times for all other compounds. The 
compounds were tested in a dilution series from 10 µM to 0.01 µM concentrations as 
described previously.39 In each assay, these results were compared with those for DMSO 
control and triclosan. Other internal controls included a curve obtained with varying 
concentrations of parasites to confirm that each assay detected differing numbers of 
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parasites, and cultures treated with a known inhibitory concentration of pyrimethamine 
and sulfadiazine as a positive control. Inhibitory index was calculated as: 
[RFU(compound) RFU(control fibroblasts)]/[RFU(DMSO control) RFU(control fibroblasts)] 100. MIC50 is 
defined as the compound concentration required to inhibit replication by 50%.  
 
Human cell proliferation assay 
Potential cytotoxic effects of the compounds were assessed using Cell Proliferation 
Reagent WST-1 (Roche), which measures the metabolic activity of viable cells. 
Confluent HFF cells in 96-well plates were treated under the same conditions as in the 
challenge assay described above, except that the cells were not infected with parasites. 
After 72 hours, the cells were incubated with WST-1 reagent for 1-2 hrs, and cell 
viability was assessed by measuring the absorbance at 420 nm of the final colored 
product, which correlates directly with cell number. All samples were tested in triplicate 
in at least two biological replicates. 
 
Inhibition of TgENR activity in vitro and enzymatic assay 
Recombinant TgENR was purified as described previously.47  A 96-well plate assay 
was used to measure the inhibition of TgENR as described previously.37, 39  Briefly, a 
SpectraMax M2 plate reader was used to monitor the activity of TgENR by consumption 
of NADH (ε340 = 6220 M-1cm-1).  Reactions were carried out in a final volume of 100 
µL in 96 well Corning UV plates. A reaction mixture was used containing 100 µM 
crotonyl-CoA (Sigma), 1 µL of DMSO (or compounds dissolved in DMSO), 5nM 
TgENR, 100 mM Na/K Phosphate pH 7.5 150 mM NaCl and 100 µM NADH.  The 
60 
 
enzymatic activity was determined by comparing the slopes of the absorbance curves for 
each well to those of the blanks in the first column of the plate. Each compound was 
measured in duplicate at 1 µM final concentration.  Potent inhibitors (>90% inhibition at 
1 µM) were further analyzed to determine IC50 values in triplicate.  Nonlinear regression 
analysis was performed using GraphPad Prism software. 
To calculate the Km and kcat values for NADH and Crotonyl-CoA we followed a 
method described previously.25  The Km and kcat were determined at variable 
concentrations of NADH (0–0.5 mM) in triplicate and a fixed concentration of crotonyl-
CoA (100 μM).  The Km and kcat for Crotonyl-CoA were determined at concentrations 
ranging from 0.8-150 µM and a fixed concentration of NADH (100µM).  Kinetic 
parameters were calculated by fitting the initial velocity data to the Michaelis–Menten 
equation using GraphPad Prism software. 
 
Thermal Shift Assay (TSA) and binding constant calculations 
A real-time PCR (RT-PCR) instrument, in the presence of Sypro Orange (an 
environmentally sensitive fluorescent dye), was used to monitor the thermal unfolding of 
TgENR alone or in the presence of ligands.  The TSA was modified from previous 
reports44-46 to measure the thermal melting temperature (Tm) of TgENR.  Real-time PCR 
tube strips (Eppendorf) were used to hold 31 µL mixtures containing final concentrations 
of 2 µM TgENR, 20 µM inhibitor and 100 µM cofactor.  The reactions were set up with a 
28 µl mixture of TgENR and buffer (20 mM HEPES pH 7.5, 100 mM NaCl) to which 1 
µL of water (or cofactor dissolved in water), 1 µL DMSO (or inhibitor dissolved in 
DMSO), and 1 µL of Sypro Orange (Sigma, Product Number S-5692 at a final 
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concentration of 5X) was added.  The reaction mixture was incubated in the RT-PCR 
machine (Applied Biosystems, Step One Plus Real-Time PCR System) for 2 minutes at 
20 °C followed by 0.2 °C increases in the temperature every 10 seconds until a final 
temperature of 80 °C was reached.  During the thermal scan, fluorescence was monitored 
using a pre-defined TAMRA filter in which an increase in Sypro Orange fluorescence 
was observed upon thermal denaturation of TgENR.    The derivative of the fluorescence 
curve was used to determine the Tm (as seen in Figure 1).  The initial Tm in the absence 
of ligands, but in the presence of DMSO, served as the baseline temperature (To) for 
determining temperature shifts (ΔTm).  All measurements were made in triplicate. 
 
Calculation of binding constant (Kd) 
The Tm values obtained in the TSA were used to calculate the dissociation constant (Kd) 
as described by Mei-Chu Lo and coworkers.44  The dissociation constant at the melting 
temperature was calculated using the equation 
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in which To is the melting temperature of TgENR with no ligands (baseline), Tm is the 
melting temperature of TgENR in complex with one or more ligands, R is the gas 
constant, ΔH is the enthalpy of protein unfolding, ΔCp is the heat capacity change on 
protein unfolding, and [LTm] is the free ligand concentration at Tm.  The two 
thermodynamic parameters (ΔH and ΔCp) were measured by Differential Scanning 
Calorimetry. A temperature scan of 0.33 mg/mL TgENR from 10 to 65 °C at 1 °C/min 
was monitored using a VP-DSC microcalorimeter (MicroCal). The change in heat 
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capacity (ΔCpTo) of 3.8 kcal/K/mol was estimated from the difference in baselines 
between the baselines of the denatured and native states.  The enthalpy (ΔHTo) was 
obtained from the area under the curve yielding a value of 228.7 kcal/mol.  The 
dissociation constant at the melting temperature was normalized to temperature T (37 °C) 











in which ΔHL(T) is the van’t Hoff enthalpy of binding at temperature T, estimated to be -
15 kcal/mol.44, 48  
 
Molecular Docking 
Molecular docking studies were performed using AutoDock 4.2,49 SwissPDB Viewer50 
and MacroModel version 8.1 (Schrodinger, LLC, New York, NY, 2012) in conjunction 
with the X-ray crystal structures of T. gondii ENR in complex with inhibitors triclosan 
(PDB ID: 202S)51 and benzimidazole (PDB ID: 1LX6)52 available from the Brookhaven 
Protein DataBank. A 10 Å radius of the active site was used to dock the synthesized 
molecules with a grid box margin of 62.  All other docking parameters were left as 
default. The obtained docking poses were analyzed using PyMol. 
 
Results and Discussion 
Parasite inhibition, host cell cytotoxicity, and inhibition of TgENR enzymatic activity 
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A structure-based approach was adopted by Freundlich and colleagues to develop 2'-, 
4'-, 5- and 6-substituted triclosan analogues against PfENR and MtInhA.27, 40-43  In the 
present study, we evaluated 18 of these analogues against Toxoplasma gondii.  The 
triclosan analogues were first tested for efficacy against T. gondii tachyzoites in vitro.  
Triclosan was also included in the assay for a direct comparison.  Type 1 RH tachyzoites 
that express Yellow Fluorescent Protein (RH-YFP) were used, allowing parasite 
proliferation to be assessed by means of a fluorometric assay, since relative fluorescence 
is directly correlated with parasite viability.  A seventy-two hour end-point was chosen to 
allow slow acting compounds to take effect.  Seven compounds emerged as the most 
effective inhibitors of T. gondii tachyzoites: 5, 8, 9, 10, 15, 16 and 17 (Table 1).  These 
compounds demonstrated an efficacy equivalent to triclosan (MIC50 of 2.8 µM), with 
MIC50 values ranging from 1.6-3.5 µM.  The compounds were also tested for cytotoxic 
activity against Human Foreskin Fibroblast host cells and exhibited no cytotoxic effects 
at the highest concentration tested (10 µM).  These results demonstrate that inhibition of 
parasite growth at lower concentrations did not result from killing the host cells, 
however, since we did not reach the MIC50 for inhibition of host cell proliferation, we do 
not know the overall selectivity of our compounds.   
The triclosan analogues were also screened in duplicate at 1 µM for inhibition of 
TgENR in an in vitro inhibition assay.  Those analogues with significant inhibitory 
activity (>90 % at 1 µM) were subsequently assayed in triplicate to determine their IC50 
values (Table 1).  A total of six analogues were potent inhibitors of TgENR with IC50 
values of less than 23 nM, similar to that of triclosan (15 nM).  None of the compounds 
with 2'-substitutions proved to have significant inhibitory activity.  This result is 
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consistent with a lack of potent activity against PfENR.43  Based on the current crystal 
structures of TgENR and PfENR bound to triclosan,51 the 2'-triclosan analogues are 
unlikely to be effective since added bulk at this position will likely result in severe steric 
clashes with the NAD+ cofactor (see docking results for further details). Potent inhibitors 
of TgENR with IC50 values in the low nanomolar range were found with substitutions at 
the 4'-, 5-, and 6- positions of triclosan.  Previous medicinal chemistry efforts targeting 
TgENR led to the discovery of several potent 4'-triclosan and 5-triclosan analogues.37, 39  
The activities of 6-triclosan analogues have not previously been described against T. 
gondii.  However, as shown in Table 1, 6-triclosan analogues such as 15 and 17 can be 
inhibitors of TgENR enzymatic activity and parasite growth.   
 
Thermal Shift Assay (TSA) 
Our current study of 18 triclosan analogues yielded six compounds with TgENR IC50 
values in the low nanomolar range (< 23 nM).  These IC50 values are similar to that of 
triclosan (15 nM) and approach the low nanomolar concentrations of TgENR enzyme 
used in our activity assay.  Because of this we could not determine which of the six 
compounds is the most potent or how they compare to triclosan with currently available 
assays.  In addition we have 14 inhibitors discovered in previous studies37, 39 which also 
inhibit TgENR with IC50 values lower than 100 nM, making 20 compounds in total.  In an 
attempt to differentiate between these inhibitors, we adapted a thermal shift assay 
(TSA)44-46 to further characterize the binding of the compounds to TgENR.   
A significant advantage of TSA over several other biophysical techniques, such as 
NMR, mass spectrometry or calorimetry, is that it can be done with higher throughput 
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without requiring large amounts of protein.44-46, 48, 53-55  This method has been previously 
employed for screening conditions which stabilize proteins;46, 56, 57 Kd calculations for 
proteins with one or two ligands;44, 45, 48, 55 as well as to determine the mode of action of 
ligand binding.55  Calculations of Kd values by TSA have been favorably compared to 
measurements done by other biophysical techniques.44 
We used the TSA to measure the melting temperature (Tm) of TgENR alone,  in binary 
complex with NADH or NAD+ cofactor, or in a ternary complex with triclosan (or 
analogues) and NADH or NAD+ bound.  Using a real time PCR machine to accurately 
control the temperature, we monitored the thermal denaturation of TgENR in the 
presence of the environmentally sensitive dye Sypro Orange.  The TSA method consists 
of monitoring the fluorescence of the dye which has a higher quantum yield when it 
interacts with hydrophobic amino acids exposed upon TgENR unfolding.  As shown in 
Figure 1, the derivative of the fluorescence intensity is marked by a sharp minimum at 
the Tm.  A shift in thermal stability occurs upon formation of a ligand complex and the 
magnitude of the shift in Tm depends on the affinity of the ligand for TgENR.  The 
observed change in Tm (ΔTm = Tm (ligand) – To (no ligand)) is used to calculate the 
binding constant (Kd) of the ligand.
44, 46  TSA can be particularly useful for proteins such 
as TgENR which have multiple ligand binding sites and can bind inhibitors and cofactor 
molecules.  In cases like this, the relative stability of the protein with different 
combinations of ligands can be used to determine the mode of action of an inhibitor.55   
 
TgENR binary complex with NADH or NAD+ 
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We studied the ΔTm of TgENR with increasing concentrations of NADH or NAD+ 
(Figure 2A).  Each data point with a nonzero ΔTm allowed us to calculate independent Kd 
values for these ligands.  For NADH, Kd values of 26 µM (ΔTm = 0.4 C) and 21 µM 
(ΔTm = 1.7 C) were measured, and for NAD
+ the Kd values were 6 mM (ΔTm = 0.4 C) 
and 6 mM (ΔTm = 1.6 C).  The Kd values resulting from the larger temperature shifts are 
likely to be the most accurate (21 µM for NADH and 6 mM for NAD+).  The Kd for 
NADH binding to TgENR is similar to the value obtained for PfENR with a Kd for 
NADH of 51.6 µM58 and that of E. coli ENR with a Kd for NADH of 5.4 µM.32   The Kd 
for NAD+ could not be determined for PfENR, except in the presence of triclosan, 
yielding an artificially low value of 15 µM58, whereas the Kd of NAD
+ for EcENR was 
determined to be 1.8 mM.32  The kinetic parameters for TgENR were calculated by using 
the enzymatic activity assay at 11 different concentrations of NADH and Crotonyl-CoA 
in triplicate, with the highest concentration of 500 µM and dilutions by factors of two for 
NADH and 0.8-150 µM for Crotonyl-CoA.  Figure 2B shows a Michaelis-Menten plot 
for TgENR with a kcat of 12 s-1 and Km of 20 µM for NADH; for Crotonyl-CoA, kcat is 26 
s-1 and Km is 40 µM (Figure 2C).  These values are similar to those of ENR enzymes 
from the apicomplexan parasites Eimeria tenella and Plasmodium falciparum (Table 
2).25, 59, 60 Although Km values cannot be equated with dissociation constants, the Km 
values for NADH are consistent with the 21 µM Kd value determined by TSA.   
 
Inhibitor mode of action determined by TSA 
The mode of action of ENR inhibition by triclosan has been well studied in several 
systems, including apicomplexan parasites, plants and bacteria. Triclosan is an 
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uncompetitive inhibitor with respect to NAD+ and forms a tight ternary 
triclosan/NAD+/ENR complex.  Consistent with this mechanism of action, we observed a 
large shift in Tm when TgENR was analyzed by TSA in the presence of triclosan and 
NAD+, but not in the absence of the cofactor (Figure 1A).  Interestingly, we also 
observed a small shift in Tm when triclosan was added to TgENR in the presence of 
NADH (Figure 1A).  Triclosan has an apparent Kd value of 186 µM for the 
TgENR/NADH complex, an affinity that is probably too weak to have physiological 
significance since this value is 100,000 times larger than the Kd of triclosan binding to the 
TgENR/NAD+ complex (1.3 nM at 100 µM NAD+ listed in Table 3).  The apparent weak 
binding of triclosan to the TgENR/NADH complex is consistent with reports of ternary 
triclosan/NADH complexes formed by ENR enzymes from E. coli,61 Haemophilus 
influenza62 and Pseudomonas aeruginosa.63   
Potent inhibition of ENR enzymes with triclosan is due to the slow formation of a tight 
ternary triclosan/NAD+/ENR complex.  PfENR is 50% identical to TgENR and serves as 
a good example of this phenomenon.  Triclosan binds to the PfENR/NAD+ complex with 
relatively low affinity (53 nM) followed by the slow (0.055 s-1 forward rate constant) 
formation of a tight binding complex with an overall inhibition constant of 96 pM.64  The 
tight binding complex involves the formation of an α-helix over the inhibitor binding site, 
a feature that was observed in the crystal structure of TgENR co-crystallized with 
triclosan and NAD+, making it very likely that triclosan inhibits TgENR through the same 
mechanism as described for other ENR enzymes.51  The slow kinetics of inhibition 
appear to be responsible for the artificially high 15 nM IC50 value of triclosan shown in 
Table 1.  The IC50 value approaches the theoretical limit (half of the 5 nM TgENR 
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concentration) when the enzyme is preincubated with triclosan and NAD+ allowing the 
inhibitory complex to form prior to initiating the assay.  In the TSA experiments, there is 
a total incubation time of about 30 minutes from the time the experiment is set up to the 
time it reaches Tm.  This allows enough time for triclosan to form the tight ternary 
complex.  To confirm this, we set up TSA experiments as explained in the Methods 
section, but allowed 2 hours of pre-incubation.  This pre-incubation time did not affect 
the Kd of triclosan for the enzyme (data not shown).  To determine the reproducibility of 
the TSA measurements, we measured the Tm in four experiments in triplicates on 
different days for TgENR alone, in binary complex with NADH and NAD+ and in the 
ternary complex TgENR/NAD+/triclosan.  The standard deviation of these measurements 
was 0.40, 0.56, 0.36 and 0.37 degree Celsius, respectively.   
All of our potent inhibitors were also tested by TSA for binding to the TgENR/NAD+ 
complex, the TgENR/NADH complex, or TgENR alone.  In all cases, the inhibitors 
displayed a similar mode of action as that of triclosan, forming a tight complex with 
TgENR/NAD+.  Figure 1B shows the TSA results for 32, a compound that differs 
significantly from the structure of triclosan, but displays a similar Tm shift profile and 
thus the same mode of action as triclosan, binding exclusively to the TgENR/NAD+ 
complex.  As shown in Figure 1, the presence of 100 µM NAD+ alone (orange curves) or 
20 µM inhibitor alone (green curves) does not shift the Tm of TgENR and thus, the ΔTm 
observed in the presence of inhibitor and NAD+ is due to the formation of the ternary 
complex. 
 
Effect of NAD+ concentration on inhibitor affinity 
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In TSA experiments we can control the concentration of the cofactors NADH and 
NAD+.  By contrast, in the enzymatic assay NADH is constantly being consumed and 
NAD+ is formed over the course of the reaction.  For TSA, we used 100 µM NADH, the 
concentration used as the starting point in the enzymatic assay.  As described above, this 
concentration is well above the 21 µM Kd of NADH, ensuring that the majority of 
TgENR forms a binary TgENR/NADH complex during the TSA experiments.  The same 
is not true for NAD+.  In the TSA experiments described above, 100 µM NAD+ was used 
whereas the Kd is 6 mM.  Under these conditions, the fraction of enzyme found as a 
binary TgENR/NAD+ complex is very small (~1.6%).   
We then analyzed the binding of two inhibitors, triclosan and 32, to better understand 
how NAD+ concentration affects the apparent Kd values determined by TSA.  We 
determined Kd values for both inhibitors at eight concentrations of NAD
+ ranging from 
2.7 µM to 6 mM.  As shown in Figure 3A, the apparent Kd for these inhibitors decreases 
as the concentration of NAD+ increases, until reaching a plateau while approaching the 
Kd of NAD
+ (6 mM).  The apparent dissociation constant of triclosan ranges from 18 µM 
(at a NAD+ concentration of 2.7 µM) to 20 fM (at a NAD+ concentration of 6 mM), 
despite the fact that NAD+ is in stoichiometric excess to TgENR (2 µM) throughout this 
concentration range.  Similarly, the Kd values for compound 32 vary from 51 µM to 689 
fM over the same range of NAD+ concentrations.  These results underscore the need to 
consider cofactor concentration when comparing Kd values for uncompetitive inhibitors 
like triclosan.  For example, a Kd value of 32 nM was reported for triclosan binding to 
PfENR58 which is similar to the value of 1.3 nM listed in Table 3 for TgENR.  However, 
the Kd for PfENR was determined with 250 µM NAD+ and the equivalent Kd value for 
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TgENR is 105 pM.  In a similar experiment, we determined the Kd values for triclosan 
and compound 32 at seven concentrations ranging from 450 nM to 333 µM, while 
keeping [NAD+] constant at 100 µM.  As expected, we found that the Kd values for both 
compounds decrease as we increase the inhibitor concentration (Figure 3B).  
We determined the Kd values for our most potent TgENR inhibitors in the presence of 6 
mM NAD+ and compared these values with those determined at 100 µM NAD+ (Table 
3).  The higher NAD+ concentration increased the apparent affinity of all of our 
inhibitors, however, the factor by which the affinity increased was not uniform across the 
compound series (Table 3).  The Kd of 25 decreased by a factor of 2,300,000 when 
NAD+ concentrations were increased, whereas the Kd of 30 only decreased by a factor of 
11,000.  Even between similar compounds such as 28 and 29 there were differences in 
the dependence of Kd on NAD
+ concentrations.  These differences may reflect the ability 
of some inhibitors to bind more tightly to TgENR in the absence of NAD+.  In the 
thermodynamic cycle shown in Figure 4A, these inhibitors would have smaller Ki values 
and larger α values corresponding to less selectivity between binding to the 
TgENR/NAD+ complex versus TgENR alone.   
We did not detect the binding of any inhibitor to TgENR when we used 20 µM 
inhibitor concentrations, however, Ki values could be well above this level.  We screened 
for inhibitor binding at higher concentrations of inhibitor (111 µM and 333 µM) but 
found that most compounds did not have measureable binding or interfered with the TSA 
at these concentrations.  Compound 29, however, appeared to bind with a dissociation 
constant (Ki) of 0.8 mM (Figure 4B).  This value of Ki allows us to estimate the 
parameter α if we can measure the affinity of compound 29 for the E•NAD complex 
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(αKi) shown in Figure 4A.  The Kd of compound 29 in the presence of 6 mM NAD+ is 
116 pM (Table 3).  We can estimate αKi using the equation for the binding of 
uncompetitive inhibitors 




in which K  is the observed dissociation constant of the inhibitor at any concentration 
of NAD+ and KNAD is the Kd of NAD
+.  Since the 6 mM concentration of NAD+ used in 
the TSA equals KNAD, this equation reduces to: 




Similar estimations of αKi can be made for all of the compounds with measured Kd 
values at 6 mM NAD+ (Table 3).  The parameter α describing the selectivity of 
compound 29 for the binary complex would then be 7×10-8.  The parameter α is 
presumably related to the ratio of Kd values shown in Table 3 in the sense that both 
numbers provide an indication of how dependent an inhibitor is on binding to the binary 
TgENR/NAD+ complex.  This phenomenon may help to guide the selection of the best 
inhibitors.  The NAD+ concentration has been measured in different cell types, including 
mouse erythrocytes and mammalian cells with values of 368 µM and a range of 300-800 
µM, respectively.65-69  Although the concentration of NAD+ in the apicoplast of T. gondii 
has not been measured, it is also likely to be well below the 6 mM Kd value.  Therefore, 
at any given time, most TgENR molecules will not have NAD+ bound.  Indeed, the large 
discrepancy between the MIC50 values in Table 1 and the extremely tight binding 
properties of some of the compounds in Table 3 may be an indication that NAD+ levels 




Inhibitor affinity to the TgENR/NAD+ complex  
The twenty compounds that we examined by TSA all had IC50 values of less than 100 
nM in the TgENR enzyme activity assay (Table 3).  The calculated Kd values at the two 
NAD+ concentrations can be used to identify the most potent compounds and how 
dependent inhibitor binding is on NAD+ concentration (Table 3).  A total of six 
compounds showed Kd values of less than 10 nM with 100 µM NAD
+, and less than 100 
fM with 6 mM NAD+ (5, 9, 10, 15, 19 and 27).  From analyzing these compounds, it is 
clear that tight binding inhibitors can contain small substituents at the 4'-position (as in 
compound 5), the 5-position (as in compound 19), or the 6-position (as in compound 15).  
As described previously37, 39, bulky substituents at the 4'- and 5-positions are 
accommodated by the TgENR active site.  Compound 27 contains a large isoxazole ring 
at the 5-position while compounds 9 and 10 contain a benzylamino moiety.  The 6-
position triclosan analogues have not been described previously for TgENR.  We show 
that modifications at this position are well tolerated as seen for compounds 15 and 17 
(see modeling data below). 
Overall, three compounds (5, 9 and 19) appear to bind to the TgENR/NAD+ complex as 
well as triclosan or better.  These compounds differ, however, in terms of how dependent 
the dissociation constants are on NAD+ concentration.  The ratio of Kd values determined 
at low and high NAD+ concentrations is 250,000 for compound 19, whereas this ratio is 
only 30,000 for compound 9 (Table 3).  As discussed above, the reduced dependence of 
compound 9 on NAD+ concentration could reflect the ability of this compound to bind 
weakly to TgENR, adding an additional route to forming the ternary 
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inhibitor/TgENR/NAD+ complex.  By contrast, compound 19 may be more dependent on 
binding to a preformed TgENR/NAD+ complex.  In this sense, compound 9 could prove 
to be a more exciting scaffold for further modification.  Since a variety of substituents are 
tolerated at the 5-position, these are possible additions that could improve the properties 
of compound 9.  Similarly, small groups such as those found in compounds 15 and 17 
could be added to the 6-position.   
 
Inhibitor Modeling 
In order to further understand the different binding properties of the various inhibitors 
studied, molecular modeling was carried out using the TgENR crystal structure and the 
molecular docking software AutoDock.49  The least effective triclosan analogues 
contained modifications on the B-ring at the 2'-position.  The close proximity of the 
NAD+ cofactor to this position on the B-ring is likely to cause a significant steric clash 
upon inhibitor binding (Figure 5A). The addition of a 5-methyl-3-carboxamide-isoxazole 
group to the A- or B- rings of triclosan resulted in a marked difference in their Kd values.  
The presence of this group at the 5-position on the A-ring (compound 27) produced a 
very potent inhibitor (Kd = 33 fM with 6 mM NAD
+), whereas this modification at the 4'-
position on the B-ring gave inhibitor 29 with 3,500 fold less affinity (Kd = 116 pM with 6 
mM NAD+). 
Molecular modeling was used to rationalize this difference in affinity.  Modeling in 
AutoDock suggested that the isoxazole group, and other large substituents37, 39 can be 
tolerated within the hydrophobic pocket surrounding the A-ring due to the mobile alpha 
helix.  Conversely, the positioning of this group on the B-ring extends towards the 
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solvent exposed entrance to the binding site, and should be able to accommodate such a 
substituent.  However, sampling the potential ligand conformations in AutoDock exposed 
a steric clash between the 4'-methylisoxazole of compound 29 and Phe243 (TgENR 
numbering) due to the rigid nature of the 5-methyl-3-carboxamide-isoxazole group.  The 
addition of a methylene group between the amide and isoxazole ring (compound 28) 
decreased the Kd by about two orders of magnitude, perhaps because the additional 
flexibility alleviated this steric clash.  
The most promising inhibitors discovered to date have a modification at the 6-position 
on the A-ring. Considering the extra bulk of the nitrile (compound 15) and the 
hydroxymethyl (compound 17) moieties, the initial steric clash observed between these 
substituents and Tyr179 must be alleviated through the movement about Cβ.  This result 
is corroborated through further modeling studies whereby the conserved Tyr179 residue 




We evaluated a series of triclosan analogues as inhibitors of Toxoplasma gondii.  The 
4'- and 5-substituted triclosan analogues are effective inhibitors of parasite growth and 
TgENR enzymatic activity.  Compounds with modifications at the 2'-position did not 
show inhibitory activity against TgENR due to steric clashes with either the NAD+ 
cofactor or the top of the binding pocket.  Modifications in the 6-position were well 
tolerated and displayed good inhibitory activity against the parasite and the TgENR 
enzyme.  Six compounds which inhibited TgENR with IC50 values in the low nanomolar 
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range were identified, but could not be further differentiated due to the limited dynamic 
range of the TgENR activity assay.  A thermal shift assay was employed to further 
characterize these compounds as well as 14 other potent inhibitors from previous 
studies.37, 39  All 20 compounds share the same mode of action and form a ternary 
complex with TgENR and NAD+, but do not bind significantly to the TgENR/NADH 
complex or to TgENR alone.  The apparent Kd values for the inhibitors were strongly 
affected by NAD+ concentration and reached a plateau as the NAD+ concentration 
approached the 6 mM Kd of NAD
+.  By comparing the apparent Kd values of the 
inhibitors at low and high NAD+ concentrations, we could identify potent compounds 
which are less dependent on NAD+ binding.  Ultimately, we were able to identify six 
compounds which bind to the TgENR/NAD+ complex in the low femtomolar range with 
affinities similar to or exceeding that of triclosan (5, 9, 10, 15, 19 and 27).  Additionally, 
four of these compounds inhibit the growth of T. gondii parasites with equal or better 
potency than triclosan (5, 9, 10 and 15).  TSA data combined with enzyme inhibition and 
parasite growth inhibition data allow for better discrimination between potent ENR 
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Figure 1. Thermal Shift Assay results for triclosan (red curves) and compound 32 (blue 
curves).  The derivatives of the fluorescence intensity curves are shown with the minima 
defining the melting temperatures (Tm). Enzyme alone – green; Enzyme/NADH – black; 






































































Figure 2. Binding and kinetic data for TgENR cofactors. A) Thermal Shift Assay results 
for the binding of NADH (red) and NAD+ (blue) to TgENR. B) Kinetic analysis of 
TgENR with NADH cofactor.  C) Kinetic analysis of TgENR with Crotonyl-CoA 













































Figure 3.  Effect of NAD+ and inhibitor concentration on the apparent dissociation 
constant of two TgENR inhibitors.  Thermal Shift Assay was used to determine apparent 
Kd values for triclosan (red) and compound 32 (blue) at different concentrations of NAD
+ 
and inhibitor.  A) The apparent dissociation constants reach a plateau as NAD+ 
concentrations approach 6 mM (the Kd of NAD
+). B) The apparent dissociation constants 
decrease as the inhibitor concentration increases to 333 µM, the highest concentration we 





















































Figure 4.  Thermodynamic cycle for formation of the ternary inhibitor/TgENR/NAD+ 
complex.  The parameter α describes the selectivity of inhibitor binding for the 
TgENR/NAD+ complex (E•NAD) and the selectivity of NAD+ binding to the 































Figure 5. Inhibitor modeling in active site of TgENR.  A) The NAD+/triclosan binding 
pocket of TgENR from a crystal structure (PDB ID: 202S)51 Ligands NAD+ and triclosan 
are shown in stick format colored by atom type. Modification of the 2' atom (marked with 
an asterisk) results in decreased affinity (see compounds 1, 2, 3 and 4) due to steric 
clashes with the NAD+ cofactor and the binding pocket. B) Molecular modeling of 
inhibitor 17 showing the position of the additional OH group and its close proximity to 



















Table 1.  Inhibitory activity, toxicity and calculated physicochemical properties of 18 
substituted triclosan inhibitors of PfENR and MtInhA.   
  Cell Growth Inhibition TgENR Inhibition 
Physicochemical 








Inhibition at  













2.8 ± 0.2 >10 98 ± 2 15 7-33 5.53 53.25 4.6 f 
1 
 
>10  >10 13 ± 13 nd  5.59 84.01 2.2 
2 >10  >10 14 ± 7 nd  7.46 41.49 0.52 
3 
 
>10  >10 22 ± 2 nd  6.74 41.49 0.33 
4 
 
>10  >10 28 ± 5 nd  5.63 50.72 4.2 
5 
 
3.1 ± 0.3 >10 97 ± 2 3 2-5 4.44 49.69 140 
6 
 
10  >10 73 ± 5 nd  4.09 58.56 12 
7 
 
>10  >10 74 ± 3 nd  3.82 84.58 7.4 
8 3.0 ± 0.8 >10 45 ± 4 nd  6.62 84.01 0.077 
9 
 
3.5 ± 0.4 >10 98 ± 2 13 10-16 6.06 41.19 1.0 
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aMIC50 of T. gondii growth with SEM from assays conducted in at least two independent 
trials each with triplicate measurements. bGrowth inhibition of human foreskin fibroblasts 
(HFF). cStandard deviation from duplicate measurements. dCalculated by ChemDraw 
Ultra 7.0. eThese data were predicted by ADMET suite 5.0 (ACD/Labs). TPSA = 
topological polar surface area; Sw = solubility in water; fThe actual water solubility for 
triclosan is 12 mg/L at 20˚C, according to US EPA - Reregistration Eligibility Decision 





1.6 ± 0.3 >10 96 ± 0 16 13-20 5.64 65.28 2.1 
11 
 
>10  >10 97 ± 1 8 7-9 5.55 29.46 2.5 
12 
 
>10  >10 78 ± 1 nd  5.82 49.69 2.8 
13 
 
>10  >10 80 ± 2 nd  5.53 49.69 4.6 
14 
 
>10  >10 41 ± 1 nd  3.82 66.14 6.9 
15 
 
2.9 ± 0.4 >10 95 ± 1 18 16-20 5.33 53.25 7.3 
16 
 
2.7 ± 0.6 >10 87 ± 2 nd  5.67 29.46 1.9 
17 
 
2.8 ± 0.7 >10 92 ± 0 23 19-26 4.44 49.69 21 
18 
 
>10  >10 81 ± 1 nd  8.26 29.46 0.024 
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tenella 60   11    Lu et al.
25 
Plasmodium 
falciparum 30   49    Perozzo et al.
59
Toxoplasma 















tenella 40   6    Lu et al.
25 
Plasmodium 
falciparum 48   10   Perozzo et al.
59 
Toxoplasma 
gondiia 40 6.7 26 1.6 This Study
a 
aKinetic measurements were determined in triplicate and the data were analyzed with 




Table 3.  Thermal shift assay results for potent inhibitors of TgENR from Table 1 and 
those described elsewhere.37, 39 







Kd (nM) at 100 µM 







15 13-22 1.3 ± 0.7 20 ± 3 62,000 
19 
 
24 16-36 1.6 ± 0.8 6.3 ± 1 250,000 
20 d 
 
38 30-48 nd nd nd 
21 d 
 
54 43-68 nd nd nd 
22 d 
 
28 22-36 nd nd nd 
23 d 
 
18 14-24 nd nd nd 
24 
 
26 23-41 680 ± 200 2,000 ± 300 350,000 
25 
 
43 35-54 600 ± 30 257 ± 40 2,300,000 
26 
 
31 26-37 560 ±  50 1,800 ± 400 310,000 
27 
 
19 17-21 6.9 ± 2 33 ± 5 210,000 
28 
 





100 79-126 19,000 ± 9,000 116,000 ± 50 170,000 
30 
 
41 31-54 9,700 ± 1,000 887,000 ± 100,000 11,000 
31 
 
30 25-34 480 ± 60 5,300 ± 2,000 90,000 
32 
 
58 42-79 440 ± 30 689 ± 40 630,000 
5 
 
3 2-5 2.1 ± 2 20 ± 1 110,000 
9 
 
13 10-16 0.8 ± 0.2 27.5 ± 6 30,000 
10 
 
16 13-20 7.3 ± 0.2 68.9 ± 70 110,000 
11 
 
8 7-9 170 ± 100 1,000 ± 3,000 170,000 
15 
 
18 16-20 9.9 ± 1 27.5 ± 6 360,000 
17 
 
23 19-26 210 ± 60 939 ± 200 220,000 
aKd of inhibitor at a NAD
+ concentration of 100 µM with standard deviation from 
triplicate measurements. bKd of inhibitor at a NAD
+ concentration of 6 mM with standard 
deviation from triplicate measurements. cRatio of Kd at 100 µM NAD
+ to Kd at 6 mM 














Redox-Dependent Lipoylation of Mitochondrial Proteins in Plasmodium falciparum 
 







Lipoate scavenging from the human host is essential for malaria parasite survival.  
Scavenged lipoate is covalently attached to three parasite proteins: the H-protein and the 
E2 subunits of branched chain amino acid dehydrogenase (BCDH) and α-ketoglutarate 
dehydrogenase (KDH).  We show mitochondrial localization for the E2 subunits of 
BCDH and KDH, similar to previously localized H-protein, demonstrating that all three 
lipoylated proteins reside in the parasite mitochondrion.  The lipoate ligase 1, LipL1, has 
been shown to reside in the mitochondrion and it catalyzes the lipoylation of the H-
protein; however, we show that LipL1 alone cannot lipoylate BCDH or KDH.  A second 
mitochondrial protein with homology to lipoate ligases, LipL2, does not show ligase 
activity and is not capable of lipoylating any of the mitochondrial substrates.  Instead, 
BCDH and KDH are lipoylated through a novel mechanism requiring both LipL1 and 
LipL2.  This mechanism is sensitive to redox conditions where BCDH and KDH are 
exclusively lipoylated under strong reducing conditions in contrast to the H-protein 
which is preferentially lipoylated under less reducing conditions.  Thus, malaria parasites 
contain two different routes of mitochondrial lipoylation, an arrangement that has not 










Plasmodium falciparum (Pf) is the deadliest of five apicomplexan parasite species 
capable of causing malaria in humans.1-4  Plasmodium spp. first invade the liver and 
undergo a single round of replication.  This phase is asymptomatic, in contrast to the 
erythrocytic stage of the parasite life cycle, which is characterized by a cyclical fever 
corresponding to multiple rounds of parasite replication within red blood cells.  
Increasing resistance to current drugs that target erythrocytic stage parasites makes it 
necessary to characterize pathways that are essential for parasite survival.5-8  One such 
pathway believed to be essential for malaria parasites is lipoate metabolism.9-11. The 
parasite contains two organelles that harbor non-redundant pathways for lipoate 
metabolism: the apicoplast -a plastid organelle- and the mitochondrion.9, 11, 12  The 
apicoplast contains a lipoate biosynthesis pathway that is critical for liver stage parasite 
development, but is dispensable in the erythrocytic stage.13-15  The mitochondrion relies 
on lipoate scavenging from the host, which has been proposed to be essential for parasite 
survival during the erythrocytic stage.9, 10, 16 
Lipoate is an essential cofactor for aerobic metabolism in oxidative decarboxylation 
reactions of 2-oxoacid complexes.  Each complex is comprised of three subunits named 
E1, E2 and E3, except for glycine cleavage system which does not form a stable 
complex.17  Lipoate is attached to a conserved lysine residue of a small lipoyl domain 
(LD) through an amide bond, serving as a swinging arm to shuffle reaction intermediates 
between active sites.18, 19  LDs are typically found at the N-terminus of the E2-subunit of 
the 2-oxoacid dehydrogenase complexes.  The H-protein of the glycine cleavage system 
(GCV) functions as a LD.  Lipoate shuffles the decarboxylated acid from the E1 subunit 
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through a thioester linkage to the core of the E2-subunit where the acyl thioester is 
converted to the corresponding Coenzyme-A (CoA) thioester by thioester exchange.  The 
dihydrolipoamide is oxidized to lipoamide by the dihydrolipoamide dehydrogenase (E3 
subunit) to reset the catalytic cycle.  The glycine cleavage system works in a similar 
fashion, but instead of three subunits it is composed of four loosely associated proteins: 
the P-protein (corresponding to the E1 subunit), the H-protein (lipoyl domain), the T-
protein (core of E2-subunit) and the L-protein, which is the E3 subunit.20 
Lipoate metabolism has been best characterized in Escherichia coli (E. coli), which has 
both biosynthetic and scavenging pathways (Figures 1A and 1C).  In E. coli, unlike in 
Plasmodium spp., these two pathways have been shown to be redundant.21  Lipoate 
biosynthesis starts with an octanoyl transferase (EcLipB), which transfers the octanoyl 
group from octanoyl-Acyl Carrier Protein (octanoyl-ACP) to a conserved lysine of the 
lipoate requiring proteins.22  Then a lipoyl synthase (EcLipA) inserts two sulfur atoms in 
positions C6 and C8 of the octanoyl group to produce the lipoyl moiety (Figure 1A).23  
The scavenging pathway uses a lipoate ligase (EcLplA) to attach lipoate to LDs in an 
ATP-dependent reaction (Figure 1C).21, 24 
Lipoate synthesis in the apicoplast of Pf follows the same pathway as the biosynthetic 
pathway described for E. coli.11, 25  However, less is known about the mechanism of 
lipoate metabolism in the parasite mitochondrion, which relies on lipoate scavenged from 
the host.9  Once lipoate is imported into the mitochondrion, there are two candidate 
enzymes, lipoate ligase 1 (LipL1) and lipoate ligase 2 (LipL2), which could catalyze the 
attachment of free lipoate to the lipoate requiring proteins.  LipL1 and LipL2, which have 
both been localized to the mitochondrion,15, 26 share about 21% sequence identity and are 
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unlikely to be paralogs.9  Three lipoate requiring proteins have been localized or 
predicted to be in the mitochondrion: branched chain amino acid dehydrogenase 
(BCDH), α-ketoglutarate dehydrogenase (KDH), and the H-protein of the GCV.12  The 
H-protein has been previously localized to the mitochondrion20 and LipL1 can lipoylate 
the H-protein in an ATP-dependent reaction.9  There is no known activity for LipL2 in 
the Pf mitochondrion, and no mechanism to lipoylate E2-BCDH or E2-KDH has yet been 
described. 
It has been proposed that lipoate scavenged from red blood cells is essential to the 
parasite.10  The halogenated compound 8-bromooctanoate (8-BrO) causes parasite growth 
inhibition and reduced lipoylation of lipoate requiring proteins in the mitochondrion is 
observed.9  The reliance on scavenged lipoate makes this an attractive process to target 
with therapeutics.  Yet, several questions remain unanswered: what is the 
compartmentalization of BCDH and KDH substrates; why does the parasite possess two 
non-paralogous lipoate ligases; what is their activity and substrate specificity against the 
three possible lipoate requiring substrates in the mitochondrion; and last, how does 8-BrO 
inhibit parasite growth? 
Here we present mitochondrial localization data for the E2 subunits of BCDH and 
KDH in Pf.  We show that LipL1 is the only active lipoate ligase in the parasite 
mitochondrion modifying the H-protein through an ATP-dependent reaction; however 
LipL1 does not recognize the other substrates, BCDH and KDH.  LipL2 does not exhibit 
ligase activity against any of the mitochondrial substrates.  Interestingly, both LipL1 and 
LipL2 are required in an ATP-dependent reaction to lipoylate BCDH and KDH.  These 
two mitochondrial lipoylation pathways show dependence on the lipoate redox state.  The 
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H-protein can be lipoylated under all conditions tested, but increased lipoylation is 
observed under less reducing conditions.  In contrast to the H-protein, BCDH and KDH 
are only lipoylated under strong reducing conditions.  Last, a lipoate analog that mimics 
the reduced form, 6,8-dichlorooctanoate (6,8-diClO), causes blood stage parasite growth 
inhibition similar to 8-BrO.  6,8-diClO can be scavenged by the parasite and attached to 
BCDH and KDH in the mitochondrion.  Modification with 6,8-diClO or 8-BrO leads to 
irreversible inactivation of these mitochondrial enzymes and subsequent parasite death.    
 
Materials and Methods 
Expression plasmids 
The malaria genome resource PlasmoDB48 was used to identify the genes encoding the 
E2 subunits of BCDH (PF3D7_0303700) and KDH (PF3D7_1320800).  Nucleotides 
encoding the first 30 amino acids of both proteins were amplified from cDNA extracted 
from erythrocytic stage Plasmodium falciparum 3D7 parasites using primers 
BCDH30.AvrII.F and BCDH30.BsiWI.R or KDH30.AvrII.F and KDH30.BsiWI.R (Table 
1).  The BCDH30 and KDH30 amplicons were digested with AvrII and BsiWI and ligated 
into parasite transfection plasmid pRL249 in frame with GFP, generating plasmids pRL2-
BCDH30GFP and pRL2-KDH30GFP.  Plasmid pRL2 is a variant of pLN
27 in which the 
calmodulin promoter has been replaced with the weaker ribosomal protein L2 promoter.50   
Ampicillin-resistant plasmid pGEXT51 was used to express lipoylation domains with 
an amino-terminal glutathione S-transferase (GST) tag.  The nucleotides encoding the 
lipoylation domain of BCDH (residues V34-L139) and KDH (residues I35-N152) were 
amplified using primers BCDH.BamHI.F100 and BCDH.EcoRI.R417 or 
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KDH.BamHI.F103 and KDH.EcoRI.R456 (Table 1).  The BCDHLD and KDHLD 
amplicons were digested with EcoRI and BamHI and ligated into pGEXT, generating 
plasmids pGEXT-BCDHLD and pGEXT-KDHLD.   
A kanamycin-resistant expression plasmid, pGEXTK, was generated by subcloning 
the kanamycin cassette from plasmid pRK58652 into the BspHI sites of pGEXT using 
primers Kan.BspHI.F and Kan.BspHI.R (Table 1).  The nucleotides encoding BCDHLD 
and KDHLD were subcloned from pGEXT to pGEXTK using BamHI and SalI, generating 
plasmids pGEXTK-BCDHLD and pGEXTK-KDHLD.  Nucleotides encoding residues 
E35-K200 (lacking the predicted N-terminal mitochondrial transit peptide) of the H-
protein (PF3D7_1132900) were amplified from an expression plasmid similar to 
pMA0079 with primers Hprot.BamHI.F and Hprot.SalI.R (Table 1).  The resulting 
amplicon was digested with BamHI and SalI, and ligated into pGEXTK, generating 
plasmid pGEXTK-Hprot. 
Expression plasmid pMALcHT9, 53 was used to express lipoylation enzymes as 
maltose binding protein (MBP) fusion proteins with a linker region composed of a 
tobacco etch virus (TEV) protease cut site followed by a six histidine affinity tag.  
Plasmid pMA0069 expressing LipL1 (PF3D7_1314600) was renamed pMALcHT-LipL1 
for this study.  A codon harmonized gene (Figure 2) encoding LipL2 (PF3D7_0923600) 
was synthesized by GeneArt and ligated to pMALcHT using the EcoRI and HindIII sites, 
generating pMALcHT-LipL2.  The gene encoding E. coli liopate ligase, EcLplA, was 
amplified from BL21 gDNA with primers LplA.BamHI.F and LplA.SalI.R (Table 1), 




Construction of lplA-/lipB- E. coli (JEG3 strain) 
In order to construct the JEG3 cell line a lipB- E. coli strain was obtained from the 
Keio deletion collection (Keio JW5089).  The kanamycin resistance cassette was 
removed by transforming JW5089 cells with the ampicillin resistant pCP20 Flp 
recombinase plasmid.54  Colonies were selected on kanamycin and ampicillin and 
incubated at 30 degrees.  One colony was transferred to liquid LB medium without 
antibiotic and incubated overnight at 42 degrees in order to induce the loss of the pCP20 
plasmid.  Colonies were selected on LB agar plates followed by replica plating on LB 
plates containing LB alone, ampicillin, or kanamycin to screen for colonies which had 
successfully lost both the kanamycin resistance cassette and the pCP20 plasmid. This 
kanamycin sensitive lipB- strain was called JEG1.  Primers LplA.H.F and LplA.H.R 
(Table 1) were designed based on the homologous regions flanking the lplA gene 
originally described by Baba and coworkers.28  These primers were used to amplify the 
kanamycin cassette flanked by FRT sites which had previously been inserted into the lplA 
locus in lplA - Keio strain JW4349.   JEG1 cells were transformed with plasmid pKD46 
which expresses λ Red recombinase (GenBank Accession number AY048746).29  
Chemically competent JEG1/pKD46 cells were prepared and transformed with 400 ng of 
the PCR product generated above and grown in SOC medium with 1 mM L-arabinose for 
2 hours at 37 degrees, after which they were selected with kanamycin on LB agar plates.  
Three colonies were screened for the lplA deletion by PCR using primers specific for the 
kanamycin cassette (K1.int.F and K2.int.R, Table 1) in combination with primers 
upstream and downstream of lplA (LplA.U and LplA.D, Table 1).  This lipB-: KanS, 
lplA-: KanR line was called JEG2.  A kanamycin sensitive line was generated as 
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described above using the pCP20 plasmid and called JEG3.  Primers LipB.U and LipB.D 
(Table 1) flanking the lipB locus were used in conjunction with primers LplA.U and 
LplA.D to verify the deletion of both genes in strain JEG3.   
 
Parasite culture for protein localization  
P. falciparum asexual blood stage cultures were maintained at 2% hematocrit in 
complete medium consisting of RPMI 1640 medium with L-glutamine (Gibco) 
supplemented with 10% human serum (Interstate Blood Bank, Memphis, TN), 25 mM 
HEPES, 0.24% NaHCO3, and 12.5 μg/ml hypoxanthine.
55  Site-specific integration 
mediated by the mycobacteriophage Bxb1 integrase was used to generate cell lines with 
the pRL2-BCDH30GFP and pRL2-KDH30GFP plasmids described above that were 
integrated into the attB locus of Dd2attB parasites.27  Transfection of parasites was 
conducted as described previously.20  Cell lines were analyzed for integration at the attB 
site by PCR analysis of genomic DNA using primers that flank the 5’ and 3’ integration 
sites.  Parasites were imaged on a Nikon Eclipse E800 epifluorescence microscope.  For 
live fluorescence, cells were incubated with 100 nM MitoTracker CMX-Ros (Invitrogen) 
and 1 μg/ml Hoechst 33258 to visualize parasite mitochondria and nuclei. 
 
Protein expression and purification 
Plasmid pMALcHT-LipL1 was transformed into BL21-Star (DE3) cells (Invitrogen) 
and co-transformed with the pRIL plasmid isolated from BL21-CodonPlus-RIL cells 
(Agilent) and plasmid pRL586 encoding the Tobacco Etch Virus (TEV) protease,52 as 
previously described.9  These cells produce LipL1 fused to an amino-terminal six 
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histidine-tag.  Transformed cells were grown to mid-log phase, and the expression of 
recombinant proteins was induced by the addition of 0.4 mM IPTG.  Cells were harvested 
after growth for 10 h at 20°C.  LipL1 was purified by metal chelate chromatography 
followed by cation exchange chromatography; LipL1 was further purified by gel 
filtration.  Plasmid pMALcHT-LipL2 was transformed into BL21-Star (DE3) and co-
transformed with the pRIL plasmid.  These cells produce LipL2 fused to an amino-
terminal MBP.  LipL2 was affinity purified using Amylose resin (NEB #E8021).   
The plasmids pGEXT-BCDHLD, pGEXT-KDHLD or pGEXTK-Hprot were 
transformed into JEG3 cells containing the pRIL plasmid.  These cells produced 
BCDHLD, KDHLD or the H-protein in the apo-form (non-lipoylated) with an amino-
terminal GST fusion protein.  The proteins were purified by GSTrap FF chromatography 
(GE Healthcare).  All cultures were grown and harvested as described for LipL1, with the 
exception that JEG3 cultures were supplemented with 5 mM sodium succinate, 5 mM 
sodium acetate and 1% glucose.  All purifications were conducted with 20 mM HEPES, 
100 mM NaCl at pH 7.5 as the base buffer.  For GST purifications, 1 mM DTT was used 
during the steps of lysis and purification.  The concentration of proteins after purification 
was determined by Bradford assay. 
 
Cell-based lipoylation assay 
The JEG3 lipoylation deficient E. coli strain was transformed with the pRIL plasmid 
and grown in LB medium supplemented with 1% glucose as a carbon source and 35 µg 
ml-1 chloramphenicol.  Sodium succinate (5 mM) and sodium acetate (5 mM) were added 
to bypass the requirement for KDH and PDH activity respectively.  JEG3/pRIL was 
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transformed with a plasmid expressing a candidate lipoate ligase (either pMALcHT-
LipL1, pMALcHT-LipL2 or pMALcHT-EcLplA) and a plasmid expressing a lipoylation 
substrate (pGEXTK-BCDHLD or pGEXTK-KDHLD) and selected using 100 µg ml
-1 
ampicillin and 50 µg ml-1 kanamycin.  Transformants were grown in LB medium and 
supplemented as described above with the addition of 200 µM R-lipoic acid (Sigma).  
Plasmids pGEXTK-BCDHLD and pGEXTK-KDHLD were also transformed into BL21-
Star (DE3) cells containing the pRIL plasmid and maintained in LB medium containing 
35 µg ml-1 chloramphenicol and 50 µg ml-1 kanamycin.  For the cell-based assay 20 mL 
cultures were grown to mid-log phase at 37 degrees and induced with 0.4 mM IPTG for 
10 hours at 20 degrees.  Cells were harvested by centrifugation and resuspended with 0.5 
mL of buffer containing 20 mM HEPES, 100 mM NaCl at pH 7.5 and lysed by 
sonication.  The cell lysates were clarified by centrifugation at 16,000 g and the 
supernatants were collected and resolved by SDS-PAGE (Invitrogen).  Lipoylated 
proteins were visualized by western blot as described in lipoate ligase assay section. 
 
Synthesis of 6,8-dichlorooctanoic acid (6,8-diClO )  
The preparation of 6,8-diClO was carried out using the ester hydrolysis conditions 
previously reported for similar analogs.56  All reagents were obtained from commercial 
sources.  A solution of ethyl 6,8-dichlorooctanoate (500 mg, 2 mmol) in EtOH (1 mL) 
was added to a suspension of LiOH (72 mg, 3.0 mmol) in 50:50 EtOH/water (1 mL) at 
room temperature.  The mixture was stirred at room temperature and monitored by thin 
layer chromatography (CH2Cl2) until the ester hydrolysis reaction appeared to be 
complete (2 h).  Water was added (20 mL), and the resulting mixture was extracted with 
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EtOAc (3 × 10 mL).  The aqueous layer containing the product was acidified to pH 2 
using 1N HCl, and extracted with EtOAc (3 × 20 mL).  6,8-Dichlorooctanoic acid was 
obtained as an oil (386 mg, 88%, Rf = 0.76 in CH2Cl2).  NMR characterization was 
performed on a 400 MHz Varian instrument.  Chemical shifts are reported in parts per 
million from tetramethylsilane.  HRMS characterization was carried out at the University 
of Illinois Mass Spectrometry Lab using ES ionization.  1H NMR (CDCl3) δ 4.10 (m, 
1H); 3.70 (m, 2H); 2.37 (t, 2H); 2.11 (m, 2H); 1.76 (q, 2H); 1.65 (m, 3H), 1.50 (m, 1H). 
HRMS: calcd. for C8H14O2Cl2: m/z 235.0277 [M + Na]
+; found: 235.0269. 
 
Lipoate ligase assay 
Purified LipL1 or LipL2 (1 µM) was incubated in reaction buffer (100 mM Na/K 
Phosphate buffer, 150 mM NaCl at pH 7.5) containing 2 mM ATP , 2 mM MgCl2, 5 mM 
TCEP, 200 µM R-lipoic acid and 10 µM apo-protein substrate: H-protein, BCDHLD, or 
KDHLD.  After incubation at 37 degrees for 1 hour, the reactions were terminated with the 
addition of gel loading buffer and analyzed by SDS-PAGE followed by transfer to 
nitrocellulose membrane.  The membranes were blocked with 5% milk in PBS for 30 
minutes, and probed with 1:5000 rabbit polyclonal α-LA (Calbiochem) for 2 hours in 1% 
milk/PBS at room temperature.  The membrane was washed with 1xPBS three times and 
then probed with 1:5000 donkey α-Rabbit IgG horseradish peroxidase (HRP) secondary 
antibody (GE Healthcare) in 1% milk/PBS overnight at 4 degrees.  The membranes were 
visualized with enhanced chemiluminescence (ECL) western substrate (Pierce) and 
exposed to film. 
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All lipoylation assays were conducted similarly using the same protein concentrations 
and base buffer.  Where indicated, ATP was omitted from the reaction and 5 mM of DTT 
or water was used instead of TCEP.  R-lipoic acid was substituted with 200 µM 6,8-
dichlorooctanoate or 200 µM 8-bromooctanoate where indicated, and in these reactions 
1:5000 rabbit polyclonal α-6,8-diClO was used as the primary probe for western blots.   
 
Amidotransferase assay 
Lipoylated H-protein (Holo H-protein) was generated by co-transforming pGEXTK-
Hprot and pMALcHT-LipL1 in JEG3 cells containing the pRIL plasmid.  These cells 
express the H-protein with an amino-terminal GST tag and LipL1 with an amino-terminal 
MBP.  One liter cultures were grown to mid-log phase and induced with 0.4 mM IPTG 
for 10 hours at 20 degrees.  Cells were harvested as described above and Holo H-protein 
was purified by affinity chromatography using a GSTrap FF column (GE Healthcare), 
followed by anion exchange using a MonoQ column (Pharmacia).  The protein 
concentration was determined by Bradford assay.  A final concentration of 10 µM of 
Holo H-protein was used in all assays, in the presence of 1 µM of LipL1 and/or LipL2 
and 10 µM of BCDHLD or KDHLD, 2 mM MgCl2, 5 mM TCEP in 100 mM Na/K 
Phosphate buffer, 150 mM NaCl at pH 7.5.  The reactions were incubated and analyzed 
as described in the lipoate ligase assay. 
 
Production of rabbit α-6,8-diClO antiserum 
Compound 6,8-diClO was conjugated to keyhole limpet hemocyanin using the Imject 
EDC mcKLH Spin Kit (Pierce).  Antibodies to the conjugate were generated in rabbits 
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using the standard protocol of the custom antibody service Cocalico Biologicals 
(Reamstown, PA).  The resulting antiserum was used in western blots where indicated 
with the label α-6,8-diClO to probe for proteins modified with either 8-bromooctanoate 
or 6,8-dichlorooctanoate. 
 
Parasite culture for 6,8-diClO growth inhibition assay and labeling 
All Plasmodium falciparum parasite lines for these experiments were grown as 
previously described9 with the following exceptions: complete media was supplemented 
with 10% Albumax (Gibco) and parasites were maintained under a 3% O2 and 3% CO2 
gas mixture.  To assess parasite growth in the presence of 6,8-diClO, Dd2attB parasites 
were synchronized with 5% sorbitol57 and seeded into 6-well plates at 0.05% parasitemia.  
Parasites were treated with 0, 25, 100, 400, and 1000 µM 6,8-diClO.  All dilutions of 6,8-
diClO were prepared in DMSO so that the final amount of DMSO in the parasite culture 
was 0.05%.  For all experiments culture media and drug were added fresh each day.  
Blood smears were made every other day to monitor parasitemia. 
For western blot analysis, asynchronous 3D7 parasites were seeded at 1% parasitemia 
and treated with 10 µM 6,8-diClO, 2 µM R-lipoic acid in 10% EtOH or vehicle for three 
days.  Parasites were isolated from red blood cells using 0.5% saponin in PBS as 
previously described.9  Parasite pellets were resuspended in RIPA Buffer (Boston 
BioProducts) supplemented with protease inhibitors (Complete Mini EDTA-free, Roche) 
and lysed by vigorous vortexing.  Insoluble debris was pelleted at 10,000 g and total 
protein of the supernatant was measured by Bradford assay.  Loading dye was added to 
the supernatant and samples were boiled for 5 min at 95 degrees and separated on a 4–
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12% gradient gel (Invitrogen) by SDS-PAGE.  Western blots were conducted as 
described above using 1:5000 rabbit α-6,8-diClO or 1:1000 rabbit α-LA (Calbiochem) as 
the primary probes.  Membranes were stripped and re-probed with 1:10,000 mouse α-
PfHsp7058 as a loading control. 
 
Results 
The E2 subunits of BCDH and KDH localize to the parasite mitochondrion 
To better understand lipoylation in the mitochondrion of Plasmodium falciparum (Pf), 
we first investigated the localization of the two lipoylated substrates predicted to be 
mitochondrial: the E2 subunits of BCDH and KDH.12  The E1β subunit of BCDH and the 
shared E3 subunit have been previously localized to the mitochondrion in Pf, showing 
that components of 2-oxoacid dehydrogenase reside in this compartment.12  The E2-
BCDH of Plasmodium berghei has been localized to the mitochondrion.14  To confirm 
the localization of the Pf E2 proteins, we generated constructs in which the first 30 amino 
acids containing the predicted mitochondrial targeting sequence of E2-BCDH and E2-
KDH were fused to green fluorescent protein (GFP).  The transgene was inserted into the 
Pf cg6 locus by mycobacteriophage integrase mediated recombination20, 27 and GFP 
fluorescence from these parasites was analyzed by live microscopy.  For both E2-GFP 
transgenic parasite lines, we observed GFP fluorescence in an organelle with branched-
like morphology that co-localized with the mitochondrial marker MitoTracker (Figure 
3A).  We confirmed expression of these constructs by western blot (Figure 3B).  These 
results demonstrate that the lipoylated E2 subunits of BCDH and KDH, in addition to the 
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H-protein, reside in the mitochondrion with the previously localized lipoate attachment 
enzymes, LipL1 and LipL2.15, 26 
 
Neither LipL1 nor LipL2 lipoylate BCDHLD or KDHLD in a cell-based lipoylation assay 
The lipoate attachment enzymes LipL1 and LipL2 are predicted to be lipoate ligases 
based on sequence homology to the E. coli lipoate ligase (EcLplA).9  LipL1 can 
complement a lipoylation deficient E. coli cell line (TM136) in minimal media by adding 
exogenous lipoate, demonstrating its activity as a ligase.9  LipL2 has been shown to have 
similar activity in TM136 cells but cell growth required four days of incubation, making 
this datum less conclusive.9  An additional factor complicating these experiments 
involves the low level of endogenous lipoylation that remains in the TM136 line.  
Apparently, transposon disruption of the lplA gene does not completely ablate lipoate 
ligase activity in TM136 (Figure 4).  Therefore, we used a lambda red recombination 
system28, 29 to generate an E. coli lplA and lipB deletion line (lplA-/lipB-) that is 
completely deficient in lipoylation activity (Figure 4).  We used this new strain (JEG3) 
to conduct cell-based lipoylation assays.  The lipoylation domains of BCDH and KDH 
(BCDHLD and KDHLD, respectively) were subcloned into a pGEX vector expressing GST 
(glutathione S-transferase) fusion proteins.  To validate that BCDHLD and KDHLD are 
competent lipoylation substrates, we expressed each domain in wild type BL21 cells and 
found that they were lipoylated by E. coli lipoylation enzymes when visualized by 
western blot using an antibody against lipoic acid (α-LA) (Figure 3C).  We next 
subcloned LipL1, LipL2 and EcLplA into a pMAL vector expressing MBP (maltose 
binding protein) fusion proteins.  We co-expressed each LD in the JEG3 cell line with 
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either Pf ligase or EcLplA.  We found that the EcLplA was sufficient to lipoylate 
BCDHLD and KDHLD (Figure 3D, lanes 1-2), but neither substrate was lipoylated in our 
in vitro cell-based assay by either putative Pf ligase when visualized by western blot 
(Figure 3D, lanes 3-6).  The lack of activity against BCDHLD and KDHLD was surprising 
since LipL1 is competent to lipoylate EcKDH and EcPDH (Figure 3D, lanes 3-4) and 
LipL2 apparently lipoylates EcPDH, albeit poorly (Figure 3D, lanes 5-6).  
 
LipL1 has substrate specific lipoate ligase activity 
To verify the unexpected behavior of LipL1 and LipL2, we decided to study the activity 
of purified recombinant enzymes. The BCDHLD and KDHLD lipoylation domains and 
truncated H-protein, lacking the N-terminal transit peptide, were expressed as GST fusion 
proteins in the lipoylation deficient JEG3 cell line and purified in the apo form.  We 
tested recombinant LipL1 and LipL2 alone against each apo substrate in the presence or 
absence of ATP, and visualized lipoylation by western blot.  As shown in Figure 5A, 
LipL1 is an active ligase only against the H-protein in an ATP-dependent reaction (top 
panel, lanes 1-2) in agreement with a previous report in which full length H-protein was 
used.9  We also found that ATP is the preferred nucleotide used by LipL1 with minor 
activity observed with GTP (Figure 6A).  Consistent with results observed in the cell-
based assay, LipL1 did not catalyze the lipoylation of BCDHLD or KDHLD (Figure 5A, 
top panel, lanes 3-6).  Similarly, we found that LipL2 did not lipoylate any of the Pf 
substrates in our in vitro ligation assay (Figure 5A, lower panel).  These results, along 
with those from the in vitro cell-based assay, show that BCDHLD and KDHLD are 
lipoylated by E. coli lipoylation enzymes, but not by either candidate Pf lipoate ligase.  
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LipL1 appears to be the only lipoate ligase with the H-protein as its only parasite 
substrate. 
 
Neither LipL1 nor LipL2 acts as an amidotransferase 
Lipoate metabolism has also been described in other systems such as Bacullis 
subtilis.30, 31  In B. subtilis, an enzyme similar to E. coli LipB (BsLipM) specifically 
octanoylates the H-protein, but does not modify other protein substrates (Figure 1B).  An 
amidotransferase is then required to transfer octanoyl (or possibly lipoyl) groups from the 
H-protein to the remaining four lipoate-dependent proteins in B. subtilis.30, 31  We tested 
whether LipL1 or LipL2 could act as an amidotransferase in an assay in which the only 
lipoate source is the holo H-protein.  We generated holo H-protein by expressing the Pf 
H-protein and LipL1 in the E. coli lipoylation deficient JEG3 cell line.  The H-protein 
was then purified in the holo form by GST affinity chromatography.  We tested the 
transferase activity of either LipL1 or LipL2 and found that neither enzyme can act as an 
amidotransferase (Figure 5B, lanes 1-6).  Even when LipL1 and LipL2 are combined in 
the same reaction, they are unable to transfer lipoyl groups from the H-protein to either 
BCDHLD or KDHLD (Figure 5B, lanes 7-9).  Thus, neither enzyme appears to be a lipoyl 
amidotransferase.  We did not test LipL1 or LipL2 for the octanoyl amidotransferase 
activity observed in B. subtilis because there is no known source of octanoyl groups (fatty 
acid biosynthesis or degradation pathways) in the parasite mitochondrion.   
 




We next tested whether both LipL1 and LipL2 are required to ligate free lipoate to 
BCDHLD or KDHLD in our in vitro ligation assay.  In these reactions, equimolar amounts 
of LipL1 and LipL2 were combined with substrate in the presence or absence of ATP.  
As shown in Figure 5C, both enzymes are required to lipoylate BCDHLD and KDHLD in 
an ATP-dependent ligation reaction (Figure 6B).  Thus, LipL1 and LipL2 function 
together as a lipoate ligase for both substrates.  Taken together, our results suggest two 
different routes by which the mitochondrial substrates of Pf are lipoylated: one in which 
LipL1 alone is sufficient to lipoylate the H-protein, and a second route in which both 
LipL1 and LipL2 are necessary to lipoylate BCDH and KDH. 
 
The two lipoylation routes differ in their redox dependence 
The lipoylation assays described in the previous sections were performed using tris(2-
carboxyethyl)phosphine (TCEP) as reducing agent.  As observed, all substrates can be 
modified in the presence of TCEP, but we found that the two lipoylation routes differed 
in their redox dependence.  In order to better understand this effect we tested three 
reducing agents, dithiothreitol (DTT), TCEP, and tris(hydroxypropyl)phosphine (THP) in 
our in vitro ligation assay.  We first tested the lipoylation of the H-protein by LipL1 in 
the presence and absence of the reducing agents.  As seen in Figure 7A, the H-protein 
can be lipoylated by LipL1 under oxidizing or reducing conditions, albeit at different 
levels.  There was enhanced activity of LipL1 under reducing conditions with DTT as 
compared to no reducing agent, perhaps because reducing agents in general help to 
protect lipoate from oxidative damage under aerobic conditions.  However, the strong 
reducing agents TCEP and THP resulted in lower LipL1 activity compared to the weaker 
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reducing agent DTT.  The lower activity of LipL1 in the phosphine reducing agents may 
have to do with the ability of agents like TCEP to reduce the dithiolane ring of lipoate.32 
We next tested the activity of both LipL1 and LipL2 in lipoylating BCDHLD and 
KDHLD under different reducing environments.  In contrast to the H-protein, BCDHLD 
and KDHLD are not lipoylated in the absence of reducing agents or under reducing 
conditions with DTT (Figure 7B, lanes 5-8).  The LipL1/LipL2 reaction only occurs in 
the presence of the strong reducing agents TCEP (Figure 7B, lane 9) or THP (Figure 8, 
top panel).  However, it is not clear from these results whether these strong reducing 
agents are acting on the lipoate redox state or affecting the enzymes (LipL1 and/or 
LipL2) and/or protein substrates (BCDHLD and KDHLD).   
 
6,8-dichlorooctanoate (6,8-diClO) is a non-redox sensitive lipoate analog 
To test whether the phosphine reducing agents are acting on lipoate or the proteins we 
used a non-redox sensitive lipoate analog, 6,8-dichlorooctanoate (6,8-diClO), which 
mimics the reduced form of lipoate (Figure 5A).  We generated antiserum that is specific 
for proteins modified with 6,8-diClO and show that LipL1 can use 6,8-diClO as a 
substrate to modify the H-protein (Figure 9B, lower panel, lane 3).  As shown in Figure 
9B, α-LA antibodies and the α-6,8-diClO antiserum are specific for their respective 
substrates, even when the western blots are significantly overexposed.  Using these 
reagents we tested the different lipoylation routes and their redox dependence in our in 
vitro assay.   
When 6,8-diClO was used as a substrate to modify the H-protein, DTT was no longer 
the most favorable reducing agent and LipL1 activity appeared to be independent of 
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redox conditions (Figure 9C).  The lower activity with TCEP (also observed in Figure 
7A) probably results from the instability of TCEP in phosphate buffer rather than a redox 
effect.33, 34  The other strong reducing agent THP only decreased LipL1 activity relative 
to DTT when lipoate, but not 6,8-diClO was used as a substrate, indicating a redox-
specific effect on lipoate itself (compare lanes 3 & 7 from Figures 7A and 9C).  A 
similar phenomenon was observed for the lipoylation of BCDHLD and KDHLD.  LipL1 
and LipL2 modified these substrates with 6,8-diClO independent of the redox 
environment (Figures 9D and 8, bottom panel).  These results demonstrate that the 
requirement for the strong phosphine reducing agents in the LipL1/LipL2 lipoylation 
reactions is actually a requirement for reduced lipoate in these reactions and that the 
proteins themselves do not need to be reduced in order to be functional (Figure 9A).  The 
redox state of lipoate appears to be important for the lipoylation of the different 
mitochondrial substrates.  BCDH and KDH are only modified when lipoate is in the 
reduced state, while the H-protein shows increased lipoylation under less reducing 
conditions. 
 
Lipoate analogs are scavenged and attached to mitochondrial substrates 
We have previously shown that the lipoate analog 8-BrO inhibits the growth of blood 
stage Pf and that treatment with 8-BrO reduces the lipoylation of the three substrates 
found in the mitochondrion of Pf.9  From these results, it was not clear whether 8-BrO 
blocked lipoate import, activation and transfer of lipoate, or if attachment of 8-BrO to the 
mitochondrial substrates inhibited their activity.  We know from the above experiments 
that 6,8-diClO can be attached to all mitochondrial substrates in our in vitro assay (see 
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Figures 9C and 9D).  To determine if 8-BrO can be attached to the parasite proteins, we 
used the α-6,8-diClO antiserum, which also recognizes proteins modified with 8-BrO.  As 
shown in Figure 10A, 8-BrO can be attached to all three mitochondrial substrates in an 
ATP-dependent reaction in our in vitro assay, suggesting that both lipoate analogs can 
potentially share a similar mode of action in malaria parasites. 
We also treated asexual blood stage parasites with 6,8-diClO at different concentrations 
as done previously for 8-BrO9  We found that 6,8-diClO significantly inhibits parasite 
growth at a concentration of 100 µM (Figure 10B), similar to growth inhibition results 
observed for 8-BrO.  To determine whether this lipoate analog is attached to 
mitochondrial proteins in the parasites, we treated cultured parasites with 0 or 10 µM 6,8-
diClO and probed the lysates with α-6,8-diClO antiserum.  Both E2-BCDH and E2-KDH 
were modified with 6,8-diClO, demonstrating that this compound can be imported into 
parasites and used by the mitochondrial lipoylation enzymes (Figure 10C).  In parallel 
experiments, we were able to detect lipoylated E2-BCDH, E2-KDH, and E2-PDH in 
parasites treated with lipoate (Figure 10C).  Lipoylation of E2-PDH is independent of 
lipoate scavenging, consistent with the finding that lipoate is synthesized in the 
apicoplast.12  We were unable to detect modification of the H-protein by either substrate, 
possibly due to low expression levels of this protein in the parasite.   
 
Discussion 
The mitochondrion of Plasmodium falciparum (Pf) relies on lipoate scavenging from 
the host.  Treatment of parasites with the lipoate analog 8-bromooctanoate (8-BrO) 
inhibited parasite growth and specifically blocked the lipoylation of mitochondrial 
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proteins.9  These results indicated that lipoate scavenging is essential for the survival of 
malaria parasites and that the lipoylation machinery in the parasite mitochondrion would 
likewise be essential.  Plasmodium spp. possess two putative lipoate ligases in the 
genome (LipL1 and LipL2) that are believed to catalyze the attachment of free lipoate to 
the lipoate requiring proteins in an ATP-dependent reaction.  In Pf, LipL1 was localized 
to the mitochondrion26 while LipL2 was reportedly found in the mitochondrion as well as 
the apicoplast organelle.15  Although the role of LipL2 in the apicoplast is not well 
defined, both LipL1 and LipL2 are involved in the lipoylation of three proteins in the 
mitochondrion of malaria parasites.  We have previously shown that one of these 
proteins, the H-protein, is mitochondrial20, and in this work we confirmed the 
mitochondrial localization of the E2 subunits of BCDH and KDH (Figure 3A).  Thus, the 
mitochondrion of erythrocytic stage Pf contains two putative lipoate ligases responsible 
for the lipoylation of three protein substrates.   
It was previously shown that LipL1 can catalyze the attachment of lipoate to full length 
H-protein in an ATP-dependent reaction9 and it was assumed that LipL1 could lipoylate 
all of the mitochondrial substrates.  Attempts to disrupt Pf LipL1 and the P. berghei 
ortholog failed16 reinforcing the idea that lipoate scavenging is essential for blood stage 
malaria parasites and that LipL1 plays a key role in this process.  In the present study, we 
observed lipoylation of the H-protein by LipL1, and found that it preferentially uses ATP 
as a nucleotide substrate (Figure 6A).  These properties make LipL1 lipoate ligase 
activity similar to that of its E. coli ortholog, EcLplA.  However, LipL1 is unable to 
lipoylate Pf BCDH and KDH (Figures 3D and 5A), while EcLplA is able to lipoylate 
both parasite proteins (Figure 3D).  It is possible that LipL1 has an unusual specificity 
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for the H-protein.  However, the ability of LipL1 to lipoylate the EcPDH and EcKDH 
when expressed in E. coli (Figure 3D) indicates that LipL1 is not highly specific for its 
substrates.  Instead, the Pf BCDH and KDH may have unique features that are not 
recognized by LipL1.  As shown in Figures 3 and 5, LipL2 does not have lipoate ligase 
activity with respect to any of the three parasite protein substrates.  
The specificity of LipL1 for the H-protein is reminiscent of the lipoylation pathways 
described for B. subtilis (Figure 1B).  In B. subtilis, an amidotransferase (LipL) with 
homology to lipoate ligases shuffles the lipoyl or octanoyl moiety from the H-protein to 
the other protein substrates.30, 31  We tested LipL1 or LipL2 alone, or in complex in an 
amidotransferase assay using lipoyl-H-protein as substrate (parasites lack a pathway to 
generate octanoyl-H-protein), but did not detect any transfer of lipoyl groups to either 
BCDH or KDH (Figure 5B).  We also considered a recent report showing that a lipoate 
ligase homolog in Saccharomyces cerevisiae (Lip3) transfers octanoyl groups from 
octanoyl-CoA to protein substrates followed by sulfur insertion by a lipoyl synthase 
(Lip5).35  We did not test LipL1 or LipL2 for this type of octanoyl transferase activity 
since the mitochondrion of malaria parasites does not contain a lipoyl synthase or a 
biochemical pathway likely to produce octanoyl-CoA.  
The lipoylation of BCDH and KDH occurs through a novel mechanism requiring both 
LipL1 and LipL2 (Figure 5C).  However, the role that each protein plays is unknown.  It 
is likely that LipL1 is responsible for at least activating lipoate, forming lipoyl-adenylate 
since this is the initial step catalyzed by LipL1 in the lipoylation of the H-protein.  The 
role of LipL2 is less clear.  It is possible that LipL2 catalyzes the transfer of lipoyl groups 
from lipoyl-adenylate to BCDH and KDH.  It is also possible that LipL2 does not have a 
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catalytic role, but instead acts as an effector helping to recruit protein substrates that 
would otherwise not be recognized by LipL1.  In either case, the LipL1/LipL2 reaction 
defines a second lipoylation pathway in the parasite mitochondrion (Figure 11).  
Attempts to disrupt the gene encoding Pf LipL2 have so far been unsuccessful,10 
suggesting that this second lipoylation pathway is essential for the survival of blood stage 
malaria parasites.   
The two mitochondrial lipoylation pathways are sensitive to redox conditions (Figure 
11).  Lipoylation of H-protein by LipL1 in the first pathway is significantly enhanced in 
the presence of DTT, but is less active in the presence of strong reducing agents such as 
TCEP and THP (Figure 7A).  The decreased lipoylation of H-protein in the presence of 
TCEP as compared to THP is likely due to the reactivity of TCEP in phosphate buffer.33, 
34  In contrast to the first pathway, the lipoylation of BCDH and KDH by the second 
pathway only occurs in the presence of TCEP or THP (Figures 7B and 8).  The redox 
potential for both DTT and lipoate has been measured to be -0.33 V and -0.32 V, 
respectively.36, 37  Currently, there is no measurement of redox potential for TCEP or 
THP, but experimental data show that TCEP readily reduces both DTT and lipoate.32  In 
the absence of reducing agent, lipoate is found in the oxidized, closed-ring form, but 
upon reduction with TCEP or THP it presumably adopts the open-ring dihydrolipoate 
form (Figure 9A).  We synthesized a structural analog (6,8-diClO) of dihydrolipoate and 
used this compound to probe the redox requirements of the second lipoylation pathway.  
Using 6,8-diClO as a substrate, all three proteins were modified regardless of the redox 
conditions (Figures 9C and 9D).  This demonstrates that the second pathway requires 
dihydrolipoate, and that the LipL1 and LipL2 enzymes are not themselves sensitive to 
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redox conditions.  These results have interesting connotations for how lipoylation may 
work and why two different routes are needed in the mitochondrion of a malaria parasite.  
Our results suggest that dihydrolipoate is needed in the mitochondrion for the 
lipoylation of BCDH and KDH.  Therefore, the redox potential of the parasite 
mitochondrion needs to be highly reducing or the parasites must employ a mechanism to 
reduce lipoate to dihydrolipoate.  While there is no measurement of the redox potential 
for the Plasmodium mitochondrion, the redox potential of the mitochondrion of HeLa 
cells has been reported to be -0.36 V.37  This value is more reducing than that of lipoate, 
and it might be sufficient to reduce lipoate to dihydrolipoate and/or maintain lipoate in 
the reduced state.  Pf has two redox systems: the gluthathione and thioredoxin systems.38  
Six proteins from these systems have been localized to the mitochondrion: thioredoxin 
reductase (TrxR - dually localized to cytosol and mitochondrion), thioredoxin-like 
protein 2 (Tlp2), peroxiredoxin (Prx1m), glutaredoxin-like protein (Glp3), and 
peroxidase-like thioredoxin peroxidase (TPxG1 – localized to the cytosol, mitochondria 
and apicoplast).38, 39  These proteins are likely involved in maintaining the redox potential 
of the mitochondrion and/or defending against oxidative stress.  It would be interesting to 
determine whether any of these proteins have the additional role of reducing lipoate.  In 
addition to these redox systems, the dihydrolipoamide dehydrogenase (E3 subunit of 
mitochondrial dehydrogenase complexes, PF3D7_1232200) likely recognizes free lipoate 
and reduces it.  This has been observed for mammalian systems, in which lipoate is 
converted to dihydrolipoate in a NADH-dependent reaction in isolated mitochondrion.36, 
40, 41  
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Inhibition of parasite growth by 8-BrO9 or 6,8-diClO (Figure 10B) indicates that one 
or more of the lipoate-dependent proteins in the mitochondrion are essential.  It is not 
clear, however, which of the three possible candidates is likely to have an essential role 
during the erythrocytic stages of parasite development.  Two of the proteins, BCDH and 
KDH, are thought to be involved in central metabolism.  The BCDH is so named because 
of its similarity to the branched chain amino acid dehydrogenases found in other 
organisms, however, malaria parasites do not appear to possess other enzymes required 
for the catabolism of branched chain amino acids.42  In light of this fact, it has been 
proposed that BCDH could act as a mitochondrial pyruvate dehydrogenase to produce 
acetyl-CoA likely required for acetylation reactions in the organelle.42, 43   A recent 
survey of protein acetylation in Pf found 421 sites in 230 proteins distributed throughout 
multiple subcellular compartments.44  Deletion of the gene encoding the E1 subunit of the 
KDH complex led to accumulation of 2-oxoglutarate and reduction of succinyl-CoA, 
establishing the role of KDH in the parasite TCA cycle.(Akhil Vaidya, manuscript in 
submission).  While this result shows that KDH activity (and the TCA cycle) is 
dispensable in blood stage parasites, it is possible that the lipoylated E2-KDH subunit has 
an additional, essential role in the parasite independent of the TCA cycle in maintaining 
the redox potential of the mitochondrion (see below).  Even though our results suggest an 
important role for either or both BCDH and KDH in parasite survival, we cannot rule out 
the essentiality of the H-protein.   
The H-protein is perhaps the most puzzling of the three lipoylated mitochondrial 
proteins.  It is unlikely to function as part of a glycine cleavage system due to the lack of 
an identifiable P-protein in the parasite genome.45.  Rather than its traditional metabolic 
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role, the H-protein could have a role in maintaining redox balance by reacting with the 
thioredoxin-like protein 2 (Tlp2).12  Tlp2 and TrxR are the only thioredoxin and reductase 
localized to the mitochondrion, but recombinant TrxR does not reduce Tlp2 in vitro, 
raising the possibility that there is another mechanism to reduce Tlp2.46  In conjunction 
with the dihydrolipoamide dehydrogenase (E3 subunit), the H-protein, or perhaps one of 
the other lipoylated proteins, could be involved in such a mechanism.  The KDH in 
Mycobacterium tuberculosis has been shown to participate in this kind of redox system47 
and a similar pathway has been proposed for malaria parasites.12  
 
Conclusions 
In the current study we show that lipoate metabolism in the mitochondrion of Pf 
follows two lipoylation routes (Figure 11).  In the first route, lipoylation of H-protein is 
catalyzed solely by the lipoate ligase LipL1.  In the second route, both LipL1 and LipL2 
are required to lipoylate the BCDH and KDH.  The two lipoylation routes are dependent 
on the redox state of lipoate, a phenomenon that has not been observed previously in any 
other system.  Furthermore, we show that all three mitochondrial substrates can be 
modified by lipoate analogs (8-BrO and 6,8-diClO) suggesting that the lethality of these 
compounds results from their attachment to essential parasite proteins by lipoylation 
enzymes.  Our results suggest that one or more of the mitochondrial protein substrates 
and by extension, LipL1 and LipL2, are essential for parasite survival making 
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Figure 1.  Lipoate synthesis and scavenging pathways. A) Lipoate synthesis as observed 
in E. coli.  Octanoyl groups from octanoyl-ACP (acyl carrier protein) are transferred to 
E2 proteins (and the H-protein) by an octanoyltransferase (LipB) followed by the 
insertion of sulfur atoms by a lipoyl synthase (LipA).  B) Lipoate synthesis as observed in 
B. subtilis.  Octanoyl groups are transferred specifically to the H-protein by 
octanoyltransferase (LipM) and are subsequently distributed to the E2 proteins by an 
amidotransferase (LipL).  As in E. coli, sulfur insertion is catalyzed by a lipoyl synthase 
(LipA).  B) Lipoate scavenging as observed in E. coli.  Lipoate scavenged from the 
external environment is attached to E2 proteins (and the H-protein) by an ATP-dependent 


































Figure 2.   Nucleotide and amino acid sequence for synthetic harmonized LipL2 based 


















Figure 3.  BCDH and KDH localization and cell-based lipoylation assays.  
A)Epifluorescent images of live P. falciparum erythrocytic-stage parasites expressing 
GFP fused to either the BCDH leader peptide (E2-BCDH30) or the KDH leader peptide 
(E2-KDH30).  The parasites were stained with MitoTracker to identify mitochondria and 
Hoescht to identify nuclei.  Image z-stacks were deconvolved and then presented as a 
single combined image.  In both cases, GFP fluorescence co-localizes with MitoTracker 
to the mitochondrion.  B)  Expression of the E2-BCDH30-GFP and E2-KDH30-GFP 
constructs.  An α-GFP western blot of parasite lysates identifies both proteins with the 
predicted molecular mass.  C)  Lipoylation of BCDHLD and KDHLD in BL21 E. coli.  The 
lipoylation domains (LD) of both the E2-BCDH and the E2-KDH are lipoylated in anti-
lipoate (α–LA) western blots of bacterial lysate, verifying that these constructs act as 
lipoylation substrates.  D)  Cell-based assay of lipoate ligase activity.  Lipoylation 
deficient JEG3 cells were used to test the activity of three candidate lipoate ligases 
(EcLplA, LipL1 and LipL2) with two lipoylation substrates (BCDHLD and KDHLD).  E. 
coli lipoate ligase (EcLplA) is sufficient to lipoylate BCDHLD and KDHLD, whereas 











Figure 4.   Analysis of lplA-/lipB- knockout E. coli cell line JEG3.  Cultures of three 
different E. coli cell lines (BL21, TM136 and JEG3) were normalized by OD600 before 
analysis by western blot using antibodies specific for lipoylated proteins (α-LA) and 
antiserum specific for E. coli Hsp70 (α-Hsp70) as a loading control.  Lipoate (LA) was 
added to the cultures grown in minimal medium (containing succinate and acetate) to 
assess lipoate ligase activity which is still present in the TM136 lplA-/lipB- disruption 














Figure 5.  In vitro lipoylation assays.  A)  Lipoate ligase activity.  Western blot analysis 
shows that LipL1 is an ATP-dependent lipoate ligase only when H-protein is used as 
substrate, while LipL2 does not display lipoate ligase activity with any substrate.  B)  
Lipoyl amidotransferase activity.  Western blot analysis shows that LipL1 and LipL2 are 
not able to transfer lipoyl groups from Holo-H-protein to either BCDHLD or KDHLD.  C)  
Combined LipL1 + LipL2 lipoate ligase activity.  Both LipL1 and LipL2 are needed for 
lipoylation of BCDHLD and KDHLD in an ATP-dependent lipoate ligase reaction.  The 




Figure 6.   Ligation reactions proceed through an ATP-dependent reaction.  A)  Western 
blot analysis of ligation reactions catalyzed by LipL1 showing that the H-protein is 
preferentially lipoylated using ATP (A) as a nucleotide source with minor activity 
observed for GTP (G), but not for CTP (C) or UTP (U).  B)  Western blot analysis of 
ligation reactions catalyzed by LipL1 and LipL2 showing that the KDHLD is 













 Figure 7.  Redox dependence of the two lipoylation routes.  A)  Redox dependence of H-
protein lipoylation.  Western blot analysis shows that lipoylation of the H-protein by 
LipL1 is enhanced in the presence of DTT.  B)  Dependence of the LipL1 + LipL2 
reaction on strong reducing conditions.  Western blots show that lipoylation of BCDHLD 
and KDHLD occur only in the presence of the strong reducing agent TCEP.  The asterisk 










Figure 8.   Modification of BCDHLD and KDHLD in the presence of THP 
LipL1 and LipL2 can modify both substrates with LA (top panel) or 6,8-diClO (lower 
panel) in a coupled reaction in the presence of the strong reducing agent THP similar to 

















Figure 9.  6,8-dichlorooctanoate is attached to all substrates independent of redox 
environment.  A)  Redox states of lipoate.  The oxidized ring form of lipoate is reduced to 
the dihydrolipoate form by treatment with TCEP or THP.  6,8-Dichlorooctanoate (6,8-
diClO) mimics the dihydrolipoate form.  B)  Modification of the H-protein by lipoate and 
6,8-diClO.  LipL1 catalyzes the attachment of lipoate as shown in the α-LA western blot 
(top panels) and 6,8-diClO as shown in the α-6,8-diClO western blot (bottom panels).  
The α-LA antibodies and the α-6,8-diClO antiserum show very little cross-reactivity.  C)  
Effect of reducing conditions on the enzymatic activity of LipL1 against the H-protein.  
The H-protein is modified by 6,8-diClO independent of the redox environment.  D)  
Effect of reducing conditions on the enzymatic activity of LipL1 + LipL2.  BCDHLD and 




Figure 10.  Modification of mitochondrial proteins with lipoate analogs.  A)  Attachment 
of 8-bromooctanoate (8-BrO) to lipoylation substrates in vitro.  An α-6-8-diClO western 
blot shows that LipL1 can attach 8-BrO to the H-protein and that LipL1+LipL2 can 
attach 8-BrO to BCDHLD and KDHLD.  B)  Growth inhibition of P. falciparum treated 
with 6,8-diClO.  The lipoate analog 6,8-diClO inhibits blood stage parasite growth in a 
dose-dependent manner.  C)  Uptake and attachment of LA and 6,8-diClO in parasite 
culture.  Western blot analysis of parasite lysate shows that treatment of P. falciparum 
parasites with either 6,8-diClO or LA results in the modification of E2-BCDH and E2-
KDH.  Lipoylated E2-PDH is derived from a synthesis pathway in the apicoplast and not 








Figure 11.  Updated mitochondrial lipoylation pathway for Plasmodium falciparum.  The 
mitochondrion relies on lipoate scavenging from the host while the apicoplast contains an 
isolated lipoate synthesis pathway.  Our data suggests that there are two routes for 
lipoylation of protein substrates in the mitochondrion.  The H-protein is solely lipoylated 
by LipL1 in an ATP-dependent reaction; this activity is enhanced under less reducing 
conditions.  Both LipL1 and LipL2 are needed for lipoylation of the E2 domains of 
BCDH (E2-BCDH) and KDH (E2-KDH) in an ATP-dependent reaction which only 








Table 1.  Primers and plasmids used in this study. 
 
Plasmid Primer Name Primer Sequence 
pMALcHT-LipL1 n/a pMA006 as described in 9 















n/a none - excised using BamHI and SalI from  pGEXT-BCDHLD 














K1.int.F  AGGCTATTCGGCTATGACTG 





The annealing portions of these sequences are underlined, endonuclease sites are marked 














A New Family of Lipoate Attachment Enzyme Catalyzes Mitochondrial Lipoate 















Mitochondrial lipoate metabolism is essential for the survival of malaria parasites.  The 
parasite mitochondrion contains two enzymes (LipL1 and LipL2) that catalyze the 
attachment of lipoate to three lipoate requiring substrates: the H-protein of the glycine 
cleavage system, the E2-subunits of branch chain amino acid dehydrogenase (BCDH) 
and α-ketoglutarate dehydrogenase (KDH).  Previous work showed that these substrates 
are lipoylated through two routes in an ATP dependent reaction with different redox 
sensitivity.  LipL1 is sufficient to lipoate the H-protein in a ligation reaction using 
oxidized or reduced lipoate.  Lipoylation of the BCDH and KDH requires both LipL1 and 
LipL2 in a ligation reaction, using exclusively reduced lipoate as substrate.  Herein we 
show that LipL1 has two activities that are essential for lipoylation of all mitochondrial 
substrates.  First, LipL1 functions as a lipoate ligase capable of lipoylating the H-protein.  
Second, it functions as a lipoate activating enzyme to generate lipoyl-AMP using reduced 
lipoate as substrate.  LipL2 is not a ligase; instead it acts as an N-lysine lipoyltransferase, 
using lipoyl-AMP as substrate.  Also, LipL2 is the only enzyme that recognizes BCDH 
and KDH.  Furthermore, LipL2 represents a new family of lipoate attachment enzymes 
conserved in malaria parasites.  Mitochondrial lipoylation in malaria parasites differs 









Plasmodium falciparum (Pf) is an apicomplexan parasite that causes malaria in 
humans.1-4  The parasite’s life cycle consists of three stages: mosquito, liver and 
erythrocytic stage.  The erythrocytic or red blood cell stage corresponds to the 
symptomatic phase.  Several drugs have been designed against this stage, but increased 
drug resistance makes it necessary to exploit pathways that are essential for parasite 
survival.3, 5-7  One pathway that is essential for parasite survival is lipoate metabolism.8, 9  
Pf contains two organelles that harbor two non-redundant pathways for lipoate 
metabolism: the apicoplast and the mitochondrion.9-12  The apicoplast contains the 
machinery needed for lipoate biosynthesis, which has been shown to be essential for 
progression from liver to erythrocytic stage.10  In contrast to the apicoplast, the 
mitochondrion relies on lipoate scavenged from the host, which has been shown to be 
essential for parasite survival during both liver and erythrocytic stage.8, 9, 13   
The cofactor lipoate is essential for aerobic metabolism in oxidative decarboxylation 
reactions of 2-oxoacid complexes comprised of three subunits named E1, E2 and E3, and 
for glycine cleavage.14  Lipoate is covalently bound to a specific lysine residue of a small 
lipoylation domain (LD) through an amide bond, forming lipoamide.15, 16  The LDs are 
typically found at the N-terminus of the E2-subunit of the 2-oxoacid dehydrogenase 
complexes.  The H-protein of the glycine cleavage system (GCV) functions as the LD.17  
Lipoamide serves as a swinging arm to shuffle reaction intermediates between active sites 
of the different subunits in the multienzyme complexes.  Lipoamide shuffles the 
decarboxylated acid from the E1 subunit through a thioester linkage to the core of the E2 
subunit where the acyl thioester is converted to the corresponding coenzyme-A (CoA) 
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thioester by thioester exchange.  Upon completion of this step, the lipoate is found in the 
reduced state (dihydrolipoamide).  The dihydrolipoamide is oxidized to lipoamide by the 
dihydrolipoamide dehydrogenase (E3 subunit) to reset the catalytic cycle.  The glycine 
cleavage system works in a similar fashion, but instead of three subunits it is composed 
of four loosely associated proteins: the P-protein (corresponding to the E1 subunit), the 
H-protein (lipoylation domain), the T-protein (core of E2 subunit) and the L-protein, 
which is the E3 subunit.17   
Lipoate metabolism has been well characterized in E. coli.  E. coli possesses the 
machinery for both biosynthesis and scavenging pathways.  In E. coli, unlike in 
Plasmodium, these two pathways have been shown to be redundant.18  Lipoate 
biosynthesis starts with an octanoyl transferase (EcLipB), which transfers the octanoyl 
group from octanoyl-Acyl Carrier Protein (octanoyl-ACP) to a conserved lysine of the 
lipoate requiring proteins.19  Then a lipoyl synthase (EcLipA) inserts two sulfur atoms in 
positions C6 and C8 of the octanoyl group to produce the lipoyl moiety.20  The second 
pathway is through lipoate scavenging, where a dedicated lipoate ligase (EcLplA) ligates 
the lipoyl group to lipoate requiring substrates in an ATP dependent reaction.18, 21  The 
EcLplA catalyzes the lipoate attachment by a two-step reaction.  First, lipoate is activated 
with ATP, forming a lipoyl-AMP intermediate that remains bound to the enzyme.  Upon 
binding of a protein substrate, the lipoyl moiety is transferred to a conserved substrate 
lysine residue.   
The EcLplA crystal structure has been determined and shown to be a two-domain 
protein consisting of a large N-terminal domain and a small C-terminal domain.21  Upon 
activation of lipoate (lipoyl-AMP formation), the EcLplA undergoes a conformational 
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change and the lipoyl-AMP adopts a U-shaped conformation at the bifurcated active 
site.21, 22  A conserved lysine residue in the EcLplA has been shown to be essential for 
catalysis, and mutation of this residue resulted in almost completely abolished overall 
lipoylation.21 
Lipoate synthesis in the apicoplast of Pf follows the same pathway as the biosynthesis 
pathway described for E. coli.10, 23  The parasite mitochondrion relies on lipoate 
scavenged from the host, which has been shown to proceed through two routes (Chapter 
4).  The parasite has two enzymes, lipoate ligase 1 (LipL1) and lipoate ligase 2 (LipL2), 
that are responsible for lipoylation of the mitochondrial substrates.  Three lipoylated 
substrates have been localized to the mitochondrion: the branched chain amino acid 
dehydrogenase (BCDH), the α-ketoglutarate dehydrogenase (KDH), and the H-protein of 
the GCV.17  LipL1 appears to be the only active ligase in the mitochondrion being 
sufficient for lipoylation of the H-protein.  Both LipL1 and LipL2 are needed for 
lipoylation of the BCDH and KDH.  These two routes show different dependence on the 
lipoate redox state: the H-protein is lipoylated when lipoate is oxidized or reduced; 
whereas the BCDH and KDH are only lipoylated when lipoate is fully reduced.  It has 
been previously shown that by treating parasites with lipoate analogues, 8-
bromooctanoate or 6,8-dichlorooctanoate, we can inhibit the activity of the mitochondrial 
lipoylation substrates and cause cell death.  These results make lipoate scavenging an 
interesting pathway to dissect for drug discovery.  Of particular interest are the individual 
mechanistic roles of LipL1 and LipL2 in the combined reaction.  Since both enzymes are 
homologous to lipoate ligases, either could be responsible for activating lipoate to lipoyl-
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AMP, recognition of protein substrates, or transfer of the lipoyl group to the protein 
substrates. 
Here we present data which show that LipL1 is the only lipoate ligase in the parasite 
mitochondrion and is the only enzyme responsible for lipoylation of the H-protein.  
Lipoylation of the BCDH and KDH proceeds through a concerted mechanism in which 
LipL1 acts as a lipoate activating enzyme producing lipoyl-AMP.  LipL2 is not a ligase, 
instead it acts as an N-lysine lipoyltransferase taking the lipoyl-AMP formed by LipL1 
and transferring the lipoyl moiety to BCDH and KDH.  LipL2 cannot catalyze this 
reaction to lipylate the H-protein.  Both LipL1 and LipL2 possess a conserved lysine 
residue, across LipL1-like and LipL2-like enzymes respectively, that is essential for their 
overall activity.  Last, LipL2 appears to represent a new family of lipoate attachment 
enzymes that is conserved across most apicomplexans.  We present in vitro lipoylation 
data to support these findings. 
 
Materials and Methods 
Lipoyl-AMP synthesis 
All reagents were obtained from commercial suppliers and used without further 
purification unless stated.  Acetonitrile was distilled after drying on CaH2 then stored over 
3Å molecular sieves. Yields of all reactions refer to the purified products. 1H spectra were 
acquired on a Bruker Avance III 500 spectrometer operating at 500 MHz. Chemical shift 
values are reported as δ (ppm) relative to DMSO at δ 2.50 ppm. The purity of synthesized 
compounds was analyzed by HPLC (Beckman Gold Nouveau System Gold) on a C18 
column (Grace Alltima 3 µm  C18 analytical Rocket® column,  53 mm × 7 mm)  using 
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triethylammonium acetate buffer (50 mM, pH 6) and methanol as eluent, flow rate 3 
mL/min, and detection at 260 nm. 
Procedures for synthesis of Lipoic Acid-Adenosine Monophosphate Mixed Anhydrides 
were based on Reed et al. (1958), with modifications.14 
(R)-5-(1,2-dithiolan-3-yl)pentanoic (((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl phosphoric) anhydride monosodium salt (Lipoyl-
AMP).  R-Lipoic acid (0.500 g, 2.42 mmol) was dissolved in acetonitrile (2.5 mL) and 
added to a solution of dicyclohexylcarbodiimide (0.250 g, 1.21 mmol) in acetonitrile (0.9 
mL) and stirred at room temperature for 30 minutes.  The resulting suspension was then 
transferred to a conical tube and centrifuged (5 minutes, 4000 rpm) to pellet the solid. 
The supernatant containing the R-lipoic acid anhydride was added to a solution of 
adenosine monophosphate monohydrate (0.442 g, 1.21 mmol) in pyridine (3.68 mL) and 
water (7.81 mL) at 0°C.  After stirring at 0°C for 50 minutes, water (10 mL) was added 
and the solution was transferred to a separatory funnel where it was washed with ice cold 
diethyl ether (2 x 10 mL) and then ice cold chloroform (2 x 10 mL).  The aqueous layer 
was collected and acetone was added to precipitate residual adenosine monophosphate, 
which was removed by centrifugation (5 minutes, 4000 rpm).  The supernatant was 
condensed under reduced pressure and then redissolved in a minimum volume of water 
and loaded on a C18 solid phase extraction column and washed with water (10 mL) and 
then eluted with acetonitrile.  Condensation in vacuo yielded the desired product in 96% 
purity (0.006 g, 0.01 mmol, 1% yield). 1H NMR (500 MHz, DMSO-d6) d 8.57 (s, 1H), 
8.31 (s, 1H), 5.94 (d, J = 5.62 Hz, 1H), 4.57 (t, J = 5.38 Hz, 1H), 4.18 (dd, J = 3.42, 4.65 
Hz, 1H), 4.04 - 4.15 (m, 10H), 3.53 - 3.64 (m, 1H), 3.13 - 3.22 (m, 1H), 3.05 - 3.13 (m, 
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1H), 2.35 - 2.44 (m, 1H), 2.36 (t, J = 7.21 Hz, 2H), 2.20 (t, J = 7.21 Hz, 1H), 1.80 - 1.91 
(m, 1H), 1.58 - 1.69 (m, 1H), 1.44 - 1.58 (m, 4H), 1.28 - 1.41 (m, 2H)  
 
Expression plasmids, protein expression and purification 
Cloning, expression and purification of the lipoylation domains of BCDH and KDH 
(BCDHLD and KDHLD respectively), the H-protein, as well as LipL1 and LipL2 were 
previously described in Chapter 4.   
The lipoylation enzymes were clone into the expression plasmid pMALcHT which 
encodes a maltose binding protein (MBP) followed by a linker region composed of a 
tobacco etch virus (TEV) protease cut site followed by a six histidine affinity tag.  
Plasmid pMALcHT-LipL1 (Chapter 4) was mutated by site directed mutagenesis to 
generate pMALcHT-LipL1K160A using primers listed in Table 1.  Plasmid pMALcHT-
LipL1K160A was transformed into BL21-Star (DE3) cells (Invitrogen) and co-transformed 
with the pRIL plasmid isolated from BL21-CodonPlus-RIL cells (Agilent) and plasmid 
pRL586 encoding the Tobacco Etch Virus (TEV) protease, as described in Chapter 4.  
These cells produce LipL1K160A fused to an amino-terminal six histidine-tag.  These cells 
were grown to mid-log phase, and protein expression was induced by the addition of 0.4 
mM IPTG.  Cells were harvested after growth for 10 h at 20°C.  LipL1K160A was purified 
by metal chelate chromatography followed by cation exchange chromatography.   
Plasmid pMALcHT-LipL2, codon optimized ligase (Chapter 4), was mutated by site 
directed mutagenesis using primers listed in Table 1 to generate pMALcHT-LipL2C93A, 
pMALcHT-LipL2C276A and pMALcHT-LipL2K219A.  Plasmids pMALcHT-LipL2C93A, 
pMALcHT-LipL2C276A and pMALcHT-LipL2K219A were transformed into BL21-Star 
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(DE3) and co-transformed with the pRIL plasmid.  These cells produce LipL2 fused to an 
amino-terminal MBP.  LipL2C93A, LipL2C276A and LipL2K219A were purified using 
Amylose resin (NEB #E8021).   
Plasmid pMALcHT-PbLipL2 (PBANKA_082459) was cloned from Plasmodium 
berghei ANKA genomic DNA (a gift from the Photini Sinnis Lab) using primers 
PbLipL2.fwd and PbLipL2.rev listed in Table 1.  Similar to LipL2 constructs, 
pMALcHT-PbLipL2 was transformed into BL21-Star (DE3) and co-transformed with the 
pRIL plasmid.  These cells produce PbLipL2 fused to an amino-terminal MBP, which 
was purified using Amylose resin. 
 
Lipoylation assays 
Purified LipL1, LipL2 or mutants (1 µM), was incubated in reaction buffer (100 mM 
Na/K Phosphate buffer, 150 mM NaCl at pH 7.5) containing 2 mM ATP, 2 mM MgCl2, 5 
mM TCEP, 200 µM R-lipoic acid and 10 µM apo-protein substrate: H-protein, BCDHLD, 
or KDHLD.  The reactions were incubated at 37 degrees for 1 hour and quenched with the 
addition of gel loading buffer and resolved by SDS-PAGE followed by transfer to 
nitrocellulose membrane.  The membranes were blocked with 5% milk in PBS for 30 
minutes, and probed with 1:5000 rabbit polyclonal α-LA891 for 1 hour in 1% milk/PBS at 
room temperature.  The membrane was washed with 1xPBS three times and then probed 
with 1:5000 donkey α-Rabbit IgG horseradish peroxidase (HRP) secondary antibody (GE 
Healthcare) in 1% milk/PBS overnight at 4 degrees.  The membranes were visualized 
with enhanced chemiluminescence (ECL) western substrate (Pierce) and exposed to film. 
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All lipoylation assays were conducted similarly using the same protein concentrations 
and base buffer.  Where indicated, ATP was omitted from the reaction and 5 mM of 
DTT, 5 mM THP or water was used instead of TCEP.  R-lipoic acid was substituted with 
1 or 10 µM R-lipoyl-AMP as the sole lipoate source, with no ATP added. 
 
Cell-based lipoylation assay 
The JEG3 lipoylation deficient E. coli strain (Chapter 4) was transformed with the 
pRIL plasmid and grown in LB medium supplemented with 1% glucose as a carbon 
source and 35 µg ml-1 chloramphenicol.  Sodium succinate (5 mM) and sodium acetate (5 
mM) were added to bypass the requirement for KDH and PDH activity respectively.  
JEG3/pRIL was transformed with a plasmid expressing a candidate lipoate ligase (either 
pMALcHT-LipL1 or pMALcHT-LipL1K160A) and selected using 100 µg ml
-1 ampicillin 
and 35 µg ml-1 chloramphenicol.  Transformants were grown in LB medium and 
supplemented as described above with the addition of 200 µM R-lipoic acid (Sigma).  For 
the cell-based assay 20 mL cultures were grown to mid-log phase at 37 degrees and 
induced with 0.4 mM IPTG for 10 hours at 20 degrees.  Cells were harvested by 
centrifugation and resuspended with 0.5 mL of buffer containing 20 mM HEPES, 100 
mM NaCl at pH 7.5 and lysed by sonication.  The cell lysates were clarified by 
centrifugation at 16,000 g and the supernatants were collected and resolved by SDS-
PAGE (Invitrogen).  Lipoylated proteins were visualized by western blot as described in 
the lipoylation assays section. 
 
Thermal Shift Assay 
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We followed a method described previously,24 with some modifications.  Real-time 
PCR tube strips (Eppendorf) were used to hold 31 µL mixtures containing final 
concentrations of 1 µM LipL1, 10 µM of ligand (R-LA, R-LA-AMP or 6,8-diClO) 
diluted in DMSO.  The reactions were set up with a 29 µl mixture of LipL1, buffer (100 
mM Phosphate pH 7.5, 150 mM NaCl and 2 mM MgCl2) and Sypro Orange (Sigma, 
Product Number S-5692 at a final concentration of 5X) to which 1 µL of DSMO (or 
ligand) and 1 µL of water or (DTT or TCEP diluted in water) were added.  The reaction 
mixture was incubated in the RT-PCR machine (Applied Biosystems, Step One Plus 
Real-Time PCR System) for 2 minutes at 20 °C followed by 0.2 °C increases in the 
temperature every 10 seconds until a final temperature of 80 °C was reached.  During the 
thermal scan, fluorescence was monitored using a pre-defined TAMRA filter in which an 
increase in Sypro Orange fluorescence was observed upon thermal denaturation of LipL1.    
The derivative of the fluorescence curve was used to determine the Tm.  The initial Tm in 
the absence of ligand, but in the presence of DMSO, served as the baseline temperature 
(To) for determining temperature shifts (ΔTm).  All measurements were made in triplicate. 
 
Production of rabbit α-LA 891 antibodies and test 
R-lipoic acid was conjugated to keyhole limpet hemocyanin using the Imject EDC 
mcKLH Spin Kit (Pierce).  Antibodies to the conjugate were generated in rabbits using 
the standard protocol of the custom antibody service Cocalico Biologicals (Reamstown, 
PA).  Specific antibodies were purified from serum using a holo-H-protein affinity 
column.  A 1 mL NHS-activated HP column (GE Healthcare) was activated with 1 mM 
HCl according to the manufacturer’s instructions.  Immediately after activation, 13.5 mg 
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of E. coli H-protein in 4 mL of reaction buffer (100 mM NaCO3H, 500 mM NaCl pH 8.3) 
was pumped through the column at a constant rate of 0.1 mL/min.  H-protein was 
circulated through the column for 2 hrs at room temperature at which point the release of 
N-hydroxysuccinimide reaction product was quantified by absorbance at 260 nM (ε = 
8600 M-1 cm-1).  The column was subsequently washed and blocked according to the 
manufacturer’s directions.  Rabbit antiserum (6 mL) was circulated over the affinity 
column at room temperature for 1.5 hrs at 0.25 mL/min. Nonspecific proteins were 
washed from the column with 10 mL of PBS followed by elution in 4 mL of 50 mM 
glycine pH 1.9.  A total of 0.68 mg of specific IgG was concentrated to 0.68 mg/mL and 
stored at -80°C in storage buffer (PBS, 50% glycerol, 0.02% NaN3).  The specific 
polyclonal antibodies were labeled α-LA891.  To test this new reagent, we generated 
lipoylated PfH-protein using LipL1, R-LA and ATP in a lipoate ligase reaction, as 
described above.  The resulting reaction mixture was used to compare α-LA891 to 
commercially available α-LA (Calbiochem) by western blot (Figure 1).   
 
Sequence identity and alignments 
The eukaryotic pathogen database25, including PlasmoDB, ToxoDB and 
PiroplasmaDB, and the Wellcome Trust Sanger Institute for Eimeria tenella26 were used 
for BLAST homology search of LipL2-like enzymes.  Amino acid sequence identity was 
calculated by using the program STRETCHER27, and sequence alignments were 





Active LipL1 is needed for lipoylation of all lipoylation substrates 
Pf mitochondrial lipoylation proceeds through two different routes.  LipL1 is sufficient 
to lipoylate the H-protein in an ATP dependent reaction, whereas both LipL1 and LipL2 
are needed to lipoylate the BCDHLD and KDHLD.  It is possible that LipL1 and LipL2 are 
lipoylating the BCDHLD and KDHLD through a concerted mechanism or by forming a 
heteromeric complex.  First, we wanted to determine whether LipL1 plays a catalytic role 
in the lipoylation of the BCDHLD and KDHLD.  To test this we produced an inactive 
mutant of LipL1 (LipL1K160A) based on sequence homology to the E. coli lipoate ligase 
(EcLplA).  Substitution of this lysine residue in EcLplA results in an enzyme that cannot 
transfer lipoyl groups and cannot form the lipoyl-AMP intermediate.21  When we 
expressed LipL1K160A in the lplA-/lipB- E. coli cell line, we observed no lipoylation of the 
E. coli substrates, which confirms the phenotype of this mutant (Figure 2A).  We then 
expressed and purified recombinant LipL1K160A and tested its activity in our in vitro 
ligation assay.  We found that this mutant cannot lipoylate the H-protein (Figure 2B, 
lanes 1-2).  We also found that BCDHLD and KDHLD are not lipoylated in the presence of 
LipL1K160A and LipL2 (Fig. 2B, lanes 3-6).  These results indicate that LipL1 has a 
catalytic role in the lipoylation of BCDHLD and KDHLD; it either catalyzes the activation 
of the lipoyl-AMP conjugate, the transfer of the lipoyl group, or both. 
In order to determine whether LipL1K160A inhibits the activation or transfer reaction, we 
synthesized the intermediate, lipoyl-AMP, and used it as the sole lipoate source in our in 
vitro assays.   As seen in Figure 2C, LipL1K160A failed to lipoylate the H-protein using 
lipoyl-AMP (lane 1), confirming that this mutant cannot catalyze the transfer reaction.  
When we combined LipL1K160A and LipL2 using the BCDHLD and KDHLD as substrates, 
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we observed lipoylation of both substrates when using lipoyl-AMP (Figure 2C, lanes 2-
5).  These data suggest that the role of LipL1 in the LipL1+LipL2 reaction is to catalyze 
the activation reaction generating lipoyl-AMP and that LipL2 is not capable of producing 
the conjugate.  Instead, it appears that LipL2 catalyzes the lipoyl transfer reaction, 
however, it is not clear whether LipL1 is required for a non-catalytic role such as 
substrate recognition.   
 
LipL2 functions as a lipoyltransferase 
From our previous results, we can conclude that LipL1 is the only enzyme capable of 
activating lipoate to form the LA-AMP intermediate, whereas LipL2 seems to be 
essential for the transfer reaction.  In order to determine whether LipL2 is sufficient to 
catalyze the transfer reaction, we tested LipL2 in the absence of LipL1 using the 
synthesized LA-AMP as the sole source of lipoate.  We found that LipL2 cannot lipoylate 
the H-protein, but it can recognize and lipoylate BCDHLD or KDHLD when lipoyl-AMP is 
supplied (Figure 3).  These results show that LipL2 acts independently as a 
lipoyltransferase against BCDHLD and KDHLD.  Combining these data with the above 
results, we can conclude that LipL1 forms the LA-AMP conjugate and can recognize 
either the H-protein as a lipoylation substrate or LipL2 as a lipoylation partner enzyme.   
LipL2 acts as a lipoyltransferase, binding LA-AMP produced by LipL1 and recognizing 
BCDHLD or KDHLD As lipoylation substrates. 
 
LipL2 is not redox sensitive 
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Given the lipoyltransferase activity of LipL2 and that the lipoylation of BCDHLD and 
KDHLD is strictly gated by the redox state of lipoate, we hypothesized that LipL2 must be 
a redox-sensitive enzyme.  To test this, we incubated LipL2 with lipoyl-AMP in the 
presence or absence of different reducing agents (DTT, TCEP and THP) and tested the 
lipoyl transfer reaction with each of the three mitochondrial substrates.  We found, as 
seen in Figure 3, that LipL2 does not recognize the H-protein under any redox conditions 
(lanes 1-4), thus confirming that H-protein is only lipoylated by LipL1.  Surprisingly, 
LipL2 did not show sensitivity to the redox state of lipoyl-AMP as both BCDHLD and 
KDHLD are lipoylated under all reducing conditions tested (Figure 3, lanes 5-12).  This 
result was puzzling given that the lipoylation of both BCDHLD and KDHLD occurs only in 
the presence of strong reducing conditions (eg. TCEP and THP, Chapter 4).   
Since LipL2 is not redox sensitive, we predict that LipL1 must be responsible for the 
redox sensitive behavior of the coupled LipL1+LipL2 reaction.  It is possible that lipoyl-
AMP or dihydrolipoyl-AMP have different binding affinity to LipL1, thus determining 
the fate of the conjugate.  By using the thermal shift assay,24 we found that oxidized 
lipoate and lipoyl-AMP bind tightly to LipL1; whereas dihydrolipoate, dihydrolipoyl-
AMP, and the reduced state analog 6,8-diClO bind with less relative affinity to LipL1 
(Table 2).  This phenomenon may be the result of conformational changes in LipL1 such 
as those observed for EcLplA rather than simply differences in binding affinity.  These 
conformational changes would then dictate whether LipL1 would recruit LipL2.   
 
A conserved lysine is essential for LipL2 activity 
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We wanted to further characterize the activity of LipL2 against the parasite substrates 
by mutational analysis.  Transfer reactions are typically catalyzed through a cysteine or 
lysine residue.  In Bacillus subtilis, an octanoyl transferase (BsLipL) catalyzes the 
transfer of the octanoyl moiety through a cysteine on which the octanoyl moiety is 
covalently attached.30, 31  We attempted to produce an inactive mutant of LipL2 by 
mutating the only two cysteines that are conserved across all Plasmodium species (C93 
and C276).  The recombinant LipL2 mutants (LipL2C93A and LipL2C276A) were tested in 
our in vitro assays. We found that the BCDHLD and KDHLD were still lipoylated (Figure 
5B, lanes 1-3 and 5-7), suggesting that LipL2 does not require a cysteine for activity and 
does not transfer lipoate through a thioester intermediate. 
In other systems, such as E. coli and mammalian, the transfer of the lipoyl moiety from 
lipoyl-AMP is facilitated by a lysine residue in the active site.32-35  This is the case for 
LipL1 as discussed above.  But unlike LipL1, LipL2 shares low sequence identity to 
EcLplA and Bos taurus N-lysine lipoyltransferase (BtLipT) (Table 3) and does not have 
an apparent conserved lysine residue when aligned to other known enzymes.  In fact, only 
the highly conserved lipoate binding motif is found in all of these enzymes, whereas the 
ATP binding motif is not conserved in LipL2-like enzymes (Figure 6A).  However, we 
observed a cluster of residues that seems to define the LipL2-like family of enzymes 
(Figure 6A, black line) and includes two well-conserved lysine residues.  We generated 
homology models of LipL2 using the program iTasser36 to better understand where these 
residues could be located relative to the active site.  The models generated by iTasser 
were based on the BtLipT structure (PDBid: 2E5A) which may be significant since the 
bovine enzyme is also a lipoyltransferase which is not capable of activating lipoate to 
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LA-AMP.  The structure of BtLipT contains a conserved active site lysine (Figure 5A) 
which aligns structurally with one of the lysine residues conserved in LipL2-like enzymes 
(Figure 6A, blue box).  In BtLipT, this lysine is essential for the transfer reaction.32, 33  
We proceeded to mutate this lysine residue in LipL2 (LipL2K219A) and tested the 
recombinant protein in our in vitro assay.  LipL2K219A is inactive in our assay when 
reacted in the presence of LipL1 in an ATP dependent reaction, thus confirming that this 
residue is essential for LipL2 activity (Figure 5B, lanes 4 and 8).  Furthermore, 
LipL2K219A alone is unable to use lipoyl-AMP as a substrate (Figure 4C), thus 
confirming that this residue is involved in the transfer reaction.  Taken together, LipL2 is 
an N-lysine lipoyltransferase similar to the BtLipT.32, 33 
 
LipL2 is a new family of lipoate transfer enzymes 
LipL2 acts as an N-lysine lipoyltransferase with low sequence identity to previously 
described lipoate attachment enzymes (Table 3).  Sequence alignment of apicomplexan 
LipL2-like enzymes shows a conserved cluster of residues that might be important for 
recognition and binding of lipoyl-AMP, which is not conserved in other lipoate 
attachment enzymes (Figure 6A).  This cluster of residues maps logically to the active 
site in our structure homology model for LipL2.  Is this “LipL2” activity conserved in 
other Apicomplexa parasites as well?  In order to investigate this, we cloned and 
expressed Plasmodium berghei LipL2 (PbLipL2) and tested its activity in our in vitro 
assay.  We found that PbLipL2 can use lipoyl-AMP as a substrate and lipoylate the Pf 
substrates BCDHLD and KDHLD but not the H-protein (Figure 6B).  This result suggests 
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Plasmodium falciparum mitochondrial lipoylation relies on lipoate scavenged from the 
host.  After lipoate is imported to the mitochondrion there are two enzymes, LipL1 and 
LipL2, which attach lipoate to the different substrates.9  We previously showed that there 
are two routes by which the substrates are modified.  First, LipL1 appears to be the only 
active ligase and is sufficient to lipoate the H-protein through an ATP dependent reaction.  
Second, both LipL1 and LipL2 are needed to lipoylate the BCDH and KDH also in an 
ATP dependent reaction.  Last, lipoylation shows redox sensitivity: the H-protein is 
lipoylated under different redox conditions; whereas the BCDH and KDH are only 
lipoylated under strong reducing conditions (eg. Tris(2-carboxyethyl)phosphine (TCEP) 
or tris(hydroxypropyl)phosphine (THP) conditions) demonstrating the need for 
dihydrolipoate in order for these substrates to be lipoylated.  From these previous results 
it was not clear if lipoylation of the BCDH and KDH proceeds through a concerted 
mechanism or by LipL1 and LipL2 forming a complex.  Also, the specific role of these 
enzymes in the parasite was not addressed. 
In order to understand the specific activity of these enzymes in the parasite we 
proceeded to mutate a conserved lysine residue in LipL1 (K160A).  We found that this 
mutation blocked lipoylation of all substrates.  This establishes that active LipL1 is 
needed for lipoylation of all substrates and is likely to be an essential enzyme.  
LipL1K160A is unable to catalyze the transfer reaction using the H-protein as substrate 
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(Figure 2C, lane 1).  While in the presence of LipL2, both BCDH and KDH were still 
lipoylated.  We concluded that LipL1 is the only active lipoate ligase in the parasite 
mitochondrion, and that LipL2 activity is essential for the lipoylation of BCDH and 
KDH.  Thus, with respect to the H-protein, LipL1 behaves like the E. coli lipoate ligase 
(Chapter 4).  
However, the lipoylation of the BCDH and KDH is more akin to the bovine system in 
which a lipoate activating enzyme (LAE) activates the free lipoate with GTP, and an N-
lysine lipoyltransferase (BtLipT) then transfers lipoate from the formed conjugate (lipoyl-
GMP) to the substrates (Figure 8).32-34, 37, 38  In Pf, we show that LipL1 acts as the LAE 
and that LipL2 acts as the N-lysine lipoyltransferase to lipoylate the BCDH and KDH, 
but with some differences between the systems.  First, LipL1 has dual activity:  1) as a 
ligase being sufficient to lipoylate the H-protein and 2) as a LAE forming the lipoyl-AMP 
conjugate.  In mammalian systems a medium chain acyl-CoA synthase has been 
identified to act as the LAE (Figure 8).38  Second, mammalian systems use GTP to 
activate lipoate,38 whereas Pf uses only ATP.  One last difference, and the most striking, 
is the difference in the dependence on the redox state of lipoate.  The LAE can recognize 
the oxidized form of lipoate and pass the conjugate to BtLipT; the assays were performed 
in the presence of 0.5 mM DTT.33  The reactions were not carried out under strong 
reducing conditions (TCEP or THP containing buffer), making difficult to conclude if the 
bovine system could lipoylate the substrate using dihydrolipoate as substrate.  By 
contrast, we have shown that Pf can only lipoylate the BCDH and KDH when lipoate is 
in the reduced state.  This is the first system in which this redox dependent lipoylation 
activity has been reported. 
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LipL1 behaves similar to EcLplA (29% identity),9 but it shows different substrate 
specificity.  Furthermore, LipL1 has 26 % sequence identity to the bovine N-lysine 
lipoyltransferase, but they share no similar activities.  The second Pf enzyme, LipL2, has 
low sequence identity to LipL1 (21%) as well as to EcLplA (12%), and no ligase 
activity.9  LipL2, structurally and functionally, seems to resemble the BtLipT despite the 
fact that they share low sequence identity (17%).  Based on our assays, LipL2 is not a 
ligase, but instead it acts as an N-lysine lipoyltransferase (Figure 5C) similar to the 
BtLipT as described above.  
The BCDH and KDH are only lipoylated by using dihydrolipoate as substrate, thus we 
hypothesized that LipL2 has a requirement for dihydrolipoyl-AMP for its activity.  We 
found that LipL2 can recognize both lipoyl-AMP and dihydrolipoyl-AMP to lipoylate the 
BCDH and KDH.  Therefore, we suggest that LipL1 must have some redox sensitivity for 
the lipoate redox state.  We found that lipoate and lipoyl-AMP bind to LipL1 with 
different affinities depending on their redox state.  The oxidized species bind relatively 
tighter to the enzyme than the reduced form.  We also found that 6,8-diClO 
(dihydrolipoate analog) binds less tightly to LipL1, with similar affinity as 
dihydrolipoate.  The binding affinity of reduced lipoyl-AMP might be important for 
transfer of the conjugate to LipL2.  Still, this might not be sufficient given that LipL1 can 
modify the H-protein under different reducing conditions with both lipoate and 6,8-diClO 
(Chapter 4).  Perhaps, the adenylation of dihydrolipoate triggers a conformational change 
on LipL1 that could be recognized by LipL2 and thus allow LipL2 to obtain the 




Both LipL1 and LipL2 are well conserved among apicomplexan parasites, suggesting 
that perhaps this mechanism of lipoate metabolism is not unique to Plasmodium.  We 
tested the activity of a rodent malaria parasite (Plasmodium berghei) LipL2 against the Pf 
substrates and found that this enzyme has lipoyltransferase activity.  Similar to Pf, the 
Plasmodium berghei genome also encodes a LipL1 enzyme.  These results suggest that 
the mechanism of lipoylation found in Plasmodium falciparum is shared in other malaria 
parasites and could be distributed broadly across other apicomplexan parasite species.   
 
Conclusions 
In the current study we expand the understanding of mitochondrial lipoylation in Pf.  
The parasite contains two lipoate attachment enzymes (LipL1 and LipL2) and three 
lipoate requiring substrates (H-protein, BCDH and KDH).  These substrates are 
lipoylated through two routes with different redox sensitivity (Figure 7).  We show that 
LipL1 is the sole lipoate ligase and it is responsible for lipoylation of the H-protein in an 
ATP dependent reaction.  The BCDH and KDH are lipoylated through a concerted 
mechanism.  LipL1 acts as a lipoate activating enzyme to generate lipoyl-AMP by using 
reduced lipoate as a substrate.  The intermediate lipoyl-AMP is the substrate of LipL2 to 
lipoylate the BCDH and KDH.  LipL2 is not a ligase as previously proposed; instead it 
acts as an N-lysine lipoyltransferase.  We show that LipL2 is not sensitive to the redox 
state of lipoyl-AMP.  It seems that LipL1, upon activation of lipoate or dihydrolipoate, 
decides the fate of the formed conjugate.  Either to lipoylate the H-protein or pass the 
conjugate to LipL2.  Last, LipL2 is part of a new family of attachment enzymes that is 
conserved throughout apicomplexan parasites.  We show that Plasmodium berghei LipL2 
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also acts as a lipoyltransferase with the same pattern of substrate specificity.  Pf 
mitochondrial lipoylation shows differences to previously described systems, including 
those found in mammals, making it an attractive drug target (Figure 8). 
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Figure 1.  Evaluation of anti-lipoamide antibodies.  We tested the specificity of 
commercially available rabbit polyclonal antiserum (Calbiochem) and purified rabbit IgG 
(bottom panel).  We found that both reagents have the same specificity against lipoylated 
proteins when tested in an in vitro reaction of LipL1 against the H-protein.  These 





Figure 2. LipL1 activity is essential for lipoylation of all substrates.  A)  LipL1 can 
complement a lipoylation deficient E. coli cell line, whereas LipL1K160A fails to lipoylate 
E. coli proteins in vivo.  B)  LipL1K160A fails to lipoylate all three mitochondrial 
lipoylation substrates in in vitro assays.  C)  LipL1K160A cannot use lipoyl-AMP as 
substrate to lipoylate the H-protein; this mutant does not prevent lipoylation of the 
BCDHLD and KDHLD in the presence of LipL2.  H-protein reactions were performed 






Figure 3.  LipL2 activity is essential for lipoylation of the BCDHLD and KDHLD.  LipL2 
acts as a lipoyltransferase by using lipoyl-AMP as substrate to lipoylate the BCDHLD and 
KDHLD, but it cannot lipoylate the H-protein.  These reactions were performed under 





Figure 4. Redox dependence of LipL2.  LipL2 does not recognize the H-protein under 
any redox conditions.  The BCDHLD and KDHLD are lipoylated independent of the 
reducing potential, thus showing LipL2 is not responsible for the redox sensitivity 





Figure 5.  LipL2 acts as an N-lysine lipoyltransferase.  A)  LipL2 iTasser homology 
model (yellow and red) using the structure of the bovine lipoyltransferase (PDBid : 2E5A) 
as a template (cyan).  The active site shows conservation of residues that could be 
essential for activity, including a conserved lysine in lipoate attachment enzymes 
involved in overall activity.  B)  Mutational analysis of LipL2 shows that Lys219 is 
essential for LipL2 activity.  C)  LipL2K219A is unable to use lipoyl-AMP as substrate.  





Figure 6.  LipL2-like enzymes are conserved across many apicomplexan parasite 
species.  A) Sequence alignment of apicomplexan LipL2-like enzymes.  The conserved 
lipoyl binding domain is underlined.  Conserved lysine 219 is highlighted by a dark blue 
box.  B) Plasmodium berghei LipL2 shows similar activity and specificity to PfLipL2.  
PbLipL2 catalyzes the lipoyltransferase reaction for substrates PfBCDHLD and PfKDHLD, 





Figure 7.  Updated scheme of mitochondrial lipoate metabolism.  Two routes exist to 
lipoylate the different substrates in the parasite mitochondrion.  LipL1 is sufficient to 
lipoylate the H-protein in a ligation reaction using both lipoate and dihydrolipoate.  
LipL1 possesses a second function as lipoate activating enzyme to generate the 
conjugate, lipoyl-AMP.  Lipoyl-AMP is used by a second enzyme, LipL2 which 





Figure 8. Comparison of parasite and mammalian lipoate scavenging mechanisms.  A)  
Dihydrolipoate is activated by LipL1, acting as a lipoate activating enzyme (LAE) 
through an ATP dependent reaction.  The formed dihydrolipoyl-AMP is taken by LipL2 
which functions as a N-lysine lipoyl transferase to lipoylate the BCDH and KDH.  B)  In 
mammals, a lipoate activating enzyme (identified to be a medium chain acyl-CoA 
synthase) catalyzes the GTP dependent activation of lipoate.  The formed conjugate, 
lipoyl-GMP, is taken by LipT which also functions as N-lysine lipoyl transferase to 
lipoylate all available substrates. 
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Table 1. Primers and plasmids used in this study. 





















The annealing portions of these sequences are underlined, endonuclease sites are marked 
by boldface type, and italics marks relevant start and stop codons. 
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Table 2. Changes in temperature of LipL1 in the presence of different ligands and 
reducing conditions as measured by thermal shift assay. 
Ligand --- DTT TCEP 
LA-AMP 6°C 3.8°C 0.1°C 
LA 4.2°C 3.2°C 0°C 
6,8-diClO 0.1°C 0.2°C 0.3°C 
 
The thermal shift assay can help to calculate binding affinity of ligands to LipL1 in the 
presence or absence of reducing agents.  The melting temperature of LipL1 is altered by 
binding of ligands that stabilize the protein.  The increase in melting temperature can be 
correlated to the binding affinity as discussed in Chapter 3.24  Oxidized lipoyl-AMP (LA-
AMP) and lipoate (LA) show a higher melting temperature difference, with respect to the 
protein with no ligand, than reduced LA-AMP and LA.  Based on this analysis, it appears 




Table 3. Sequence identity between known lipoate attachment enzymes. 
  PfLipL1 PfLipL2 PbLipL2 EcLplA BtLipT 
PfLipL1 100% 21% 21% 29% 26% 
PfLipL2 --- 100% 44% 13% 15% 
 
Plasmodium falciparum (Pf); Plasmodium berghei (Pb); Escherichia coli (Ec) lipoate 






























During this work I have described human pathogens that affect millions of people, 
causing significant morbidity.  My work focused on two Apicomplexan parasites: 
Toxoplasma gondii and Plasmodium falciparum (Pf).  I made used of biochemical and 
biophysical methods to better understand fatty acid metabolic pathways that are essential 
for the survival of these parasites.   
The first part of my work is a component of a multi-lab collaboration that has focused 
on optimizing the potency and drug-like properties of triclosan: a known biocide that 
targets the last step of Fatty Acid Synthesis type II (FAS-II) of Toxoplasma gondii with 
high specificity.1, 2  Several chemical modifications have been made to the rings of 
triclosan to make the molecule more “druggable”.3, 4 I have designed an assay to calculate 
inhibition and IC50 values of triclosan and analogues in a 96-well plate using a plate 
reader.3-5  This assay allowed us to compare the specificity of the analogues relative to 
triclosan and served as a guide for further modifications generated by our medicinal 
chemistry collaborators.  For potent compounds, however, the enzymatic activity assay 
was not sensitive enough to discriminate between compounds.  Our assay requires a final 
concentration of TgENR of 5 nM in order to achieve a robust signal to noise ratio.  Thus, 
we will never be able to measure an IC50 value of less than 2.5 nM.    
To address the lack of sensitivity of the enzymatic assay, I developed a thermal shift 
assay6, 7 to calculate the binding affinity of the compounds to the enzyme.5  In this assay 
we determine the melting temperature of the enzyme with or without ligands.5  The 
melting temperature can be correlated to the relative binding affinity of the ligand to the 
enzyme.  The assay has a great dynamic range, allowing for binding affinity calculations 
from millimolar to femtomolar values.5  This allowed us to better discriminate between 
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potent compounds and added a second method to help decide what compounds are 
promising for further optimization.  This assay also helped us to determine the mode of 
action of the compounds.5  ENR enzymes have two binding sites, one for the cofactor 
NADH and one for the acyl-ACP (or acyl-CoA) species.  Triclosan is known to occupy 
the acyl binding site of ENR enzymes, however, it does not bind to the enzyme alone.  
Instead, triclosan forms a ternary complex with the enzyme and a byproduct of catalysis, 
NAD+.5, 8  I tested whether the different analogues had a similar binding mode of action 
as triclosan does, and found that all compounds bind to the enzyme primarily in the 
presence of NAD+.  I was able to measure the binding of one compound to TgENR in the 
absence of NAD+ and found that the Kd was too high to be physiologically relevant (0.8 
mM).  Furthermore, I found that the compounds appear to bind tighter to the enzyme as 
the concentration of NAD+ increases.5  The strong dependence on cofactor concentration 
could provide an explanation for why compounds that bind to TgENR very tightly do not 
perform very well in parasite growth inhibition experiments.  If NAD(H) levels tend to be 
low in the apicoplast organelle, it would make it hard for triclosan or any analogue 
sharing its mechanism of action to inhibit the enzyme in vivo and reduce parasite growth. 
The second and main part of my work focused on understanding lipoic acid metabolism 
in Pf.  Lipoic acid or lipoate is an eight carbon fatty acid with sulfur atoms at positions 6 
and 8.  Lipoate is an essential cofactor, attached to a specific lysine of lipoate requiring 
enzymes.9  From previous studies I knew that two organelles required lipoate in malaria 
parasites: the apicoplast and the mitochondrion.10, 11  These organelles are referred to in 
the singular since each parasite contains one apicoplast and one mitochondrion.  The 
apicoplast relies on lipoate biosynthesis and contains only one enzyme that requires 
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lipoate, pyruvate dehydrogenase (PDH).12  The PDH function is to generate acetyl-CoA, 
which feeds into FAS- II to elongate fatty acids.12, 13  This is true for both Plasmodium 
spp. and Toxoplasma gondii.12, 14  But contrary to the essentiality of these processes in T. 
gondii, both PDH and FAS-II are only essential in Pf liver stages; therefore I did not 
focus my work on lipoate biosynthesis.12, 15, 16   
Contrary to the apicoplast, the mitochondrion relies on lipoate scavenged from the 
host.10  These two pathways are non-redundant.  My work focused on understanding the 
mechanism of action and specificity of two putative lipoate ligases involved in lipoate 
scavenging in the mitochondrion.  I determined that after lipoate is trafficked to the 
mitochondrion, a known lipoate ligase (LipL1) can activate the cofactor through an ATP-
dependent reaction to form lipoyl-AMP.  Depending on the redox state of lipoate, 
oxidized or reduced (lipoate vs. dihydrolipoate, respectively), LipL1 can either only 
lipoylate the H-protein or transfer lipoyl-AMP to LipL2 in a concerted mechanism to 
lipoylate the BCDH and KDH.  I determined that two routes exist in the mitochondrion 
for the lipoylation of the substrates: lipoate is used solely to lipoylate the H-protein; 
dihydrolipoate can be used to lipoylate all substrates.  LipL2 is a second predicted lipoate 
ligase located in the mitochondrion, but it does not function as a ligase.  Instead, it acts as 
an N-lysine lipoyltransferase, specifically against the BCDH and KDH.  I also found that 
this enzyme belongs to a new family of lipoate attachment enzymes conserved 
throughout most species of the phylum Apicomplexa.   
Lipoate scavenging is essential for the survival of malaria parasites in both blood and 
liver stages.  Previous studies showed growth inhibition by treating parasites with a 
lipoate analog, 8-bromooctanoate (8BrO).10  I found that the mode of action of this 
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analog is by irreversible modification of the mitochondrial substrates.  Thus, 8BrO is a 
substrate of the lipoylation enzymes and an inhibitor of the mitochondrial enzymes to 
which it is attached.  I also found the same to be true for a dihydrolipoate analog, 6,8-
dichlorooctanoate (6,8-diClO), where we see modification of the protein substrates by 
Western blot in conjunction with parasite growth inhibition.  Perhaps in vivo, the need for 
oxidized or reduced lipoate is a metabolic requirement for the parasite.  Still, several 
questions remain unanswered. 
How does LipL1 discriminate between oxidized and reduced lipoate?  One possibility 
is that reduced dihydrolipoate and dihydrolipoyl-AMP binds loosely to LipL1 and the 
conjugate is more readily transferred to LipL2, as discussed in Chapter 5.  A second 
possibility is that there is a conformational change in LipL1 upon binding or formation of 
dihydrolipoyl-AMP that allows LipL1 to interact with LipL2.  Without this 
conformational change, LipL1 bound to oxidized lipoyl-AMP is only able to interact with 
the H-protein.  It would be interesting to obtain an X-ray crystal structure of LipL1 in the 
presence of both lipoyl-AMP and 6,8-dichlorooctyl-AMP, which would give an insight to 
the mode of action of LipL1.  I attempted to crystallize LipL1, but it presented challenges 
during purification and crystals that did not diffract beyond 4Å (see appendix).   
I have mentioned that dihydrolipoate (reduced lipoate) is a requirement for the 
lipoylation of the BCDH and KDH.  This raises the question of how is lipoate reduced 
after being scavenged to the mitochondrion?  One possibility is that both lipoate and 
dihydrolipoate exist in the red blood cell and the parasite can scavenge both.  It is more 
likely that the parasite scavenges only oxidized lipoate, since it has to cross several 
membranes and lipoate is more hydrophobic.  In order to reduce lipoate the 
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mitochondrion environment could be reducing enough to reduce lipoate (<-.32mV).17  
We may be able to demonstrate this by using a genetically modified green fluorescence 
protein (roGFP) that is sensitive to redox potential.18, 19  This roGFP has been modified to 
have two cysteines near where the chromophore forms, changing the spectroscopic 
properties of the chromophore depending on the redox environment.18, 19  The two 
cysteines can form disulfide bonds in more oxidizing environments or break the disulfide 
in more reducing environments.  One can measure the emission (λ =508 nM) of roGFP 
by exciting at two different wavelengths (λ =400 nM and 475 nM).  The emission ratio 
after excitation at 400 nM or 475 nM can be correlated to how reducing the environment 
is.   I ordered this plasmid and in collaboration with Krista Matthews, we designed a 
transfection plasmid encoding roGFP with an amino-terminal mitochondrial transit 
peptide.  Parasites transfected with this plasmid have fluorescent mitochondria, 
demonstrating that roGFP can be produced and trafficked to the parasite mitochondrion 
(work was done by a Krista Matthews).  The next step is to calibrate the relative 
fluorescence under reducing and oxidizing conditions in order to make redox 
measurements.  This work is still in progress.   
Another possibility, as discussed in Chapter 4, is that the dihydrolipoamide (E3 subunit 
of lipoylated complexes) could reduce free lipoate.20, 21  I cloned and purified the 
mitochondrial Pf E3 subunit and tested its activity on free lipoate.  I found that the E3 can 
catalyze the reverse reaction, lipoate to dihydrolipoate using NADH (Figure 1).   We can 
monitor this reaction at λ = 340 nm and calculate kcat and Km for lipoate (Figure 2).  The 




While this is not conclusive evidence of what happens in the parasite, these in vitro data 
support the hypothesis that this process could happen in the mitochondrion. 
The discovery that there are two routes for mitochondrial lipoylation in malaria 
parasites raises the question of why the mitochondrial substrates require different 
lipoylation mechanisms.  To address this question, it is important to understand what 
roles the three mitochondrial substrates play in parasite biology.  As mentioned in 
Chapter 4, only the KDH has been shown to have its canonical role as part of the citric 
acid cycle.  Knockouts of the E1 subunit of the KDH were viable, showing that this role 
is not essential for parasite survival during the blood stage.  The roles of the BCDH and 
H-protein are harder to discern because the parasite genome does not appear to encode 
partner enzymes necessary for their function.  A possibility for all substrates is that they 
have moonlighting activity.  There are several ways to approach this question.  First, the 
genes encoding the different substrates could be knocked out in the parasite.  This is a 
challenging kind of experiment to conduct in Pf since double crossover homologous 
recombination is a rare event and difficult to select for.  An alternative approach is to use  
single crossover homologous recombination to attempt gene disruptions in the parasite 
and these attempts are currently ongoing.  For technical reasons, gene deletion is more 
feasible in the rodent parasite Plasmodium berghei.  An added value in doing gene knock 
outs in P. berghei is that the resulting strains can be examined in all life cycle stages 
(mosquito, liver and blood stage) using mice.  This kind of experiment will address the 
essentiality of the lipoylated substrates and reveal lifecycle phenotypes for those that can 
be deleted.  If the knock outs are viable one could perform metabolomics studies to look 
for aberrant product accumulation as done by other groups.23, 24   
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Last, in vitro experiments could be designed to address the question of whether the E2-
KDH (or other lipoylated substrates) along with the E3 subunit can serve as the 
thioredoxin reductase as mentioned in Chapter 4.  I have purified the E3 subunit and 
showed that it is active.  I have E. coli clones containing expression plasmids of the E2-
BCDH, E2-KDH and H-protein which will produce these proteins with an amino-
terminal GST tag.  These substrates can be expressed and purified in the holo form and 
tested to determine their roles as a reductase as done for other proteins.25-27  The 
thioredoxin reductase dually localized to the mitochondrion and the cytosol, did not 
recognize downstream enzymes involved in the mitochondrial thioredoxin system in in 
vitro experiments.25  It would be interesting to address whether the E3 along with a 
lipoylated substrate could act as such a thioredoxin reductase. 
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Figure 1.  The dihydrolipoamide dehydrogenase (E3 subunit of lipoylated complexes) 
can catalyze the re-oxidation of the lipoyl moiety using NAD+.  A)  A possible activity 
for this enzyme is that it could use free lipoate and reduce it, as shown for other 
systems.20, 21  We can monitor the consumption of NADH by the E3 subunit in the 
presence of lipoate, which would mean that dihydrolipoate is being formed.  B)  An 
output from the SpectraMax M2 plate reader showing the consumption of NADH over 









Figure 2.  Kinetic analysis of E3 subunit using lipoate as a substrate.   Initial velocity 

























Plasmodium falciparum lipoate ligase 1 (LipL1) appears to be the only lipoate ligase in 
the malaria parasite.  Furthermore, it has two roles: as lipoate ligase only against the H-
protein and as lipoate activating enzyme generating the intermediate lipoyl-AMP, which 
is subsequently used by Plasmodium falciparum lipoate ligase 2 (LipL2).  These roles 
have distinct characteristics previously discussed, but one striking difference is the 
sensitivity to the lipoate redox state.  When lipoate is oxidized or in the closed ring form, 
the H-protein is the only substrate lipoylated; whereas when lipoate is reduced or in the 
open ring form all substrates are lipoylated.  Our data suggest that LipL1, upon activation 
of lipoate under different redox states, defines what substrates can be lipoylated.  For this 
reason, among others, LipL1 X-ray crystal structure would be very informative to better 
understand mitochondrial lipoylation. 
LipL1 is easily expressed and purified in E. coli with high yield.  One challenge during 
purification of full-length LipL1 (flLipL1) is that it is cleaved during purification (Figure 
1A).  LipL1 contains a low com plexity region, which is not conserve in other described 
lipoate ligases (Figure 1B).  This region it is f ound in other Plasmodium species, but 
with no conservation of sequence or size.  Am ino acid sequencing revealed that cleavage 
initially occurs between Lys264 and Glu265, which is found in this low com plexity 
region.  Mutation of this residue (K264A) did not prevent degradation during purification 
(Figure 1C).  It appears that degrada tion occurs during expression in E. coli and it 
continues during purification.  Use of protease  inhibitors did not satisfactorily prevent 
degradation of LipL1.  Still, LipL1 can be cr ystallized and the crys tals diffract to low 
resolution (Figure 2).  Crystallization of LipL1 was not  always reproducible and crystals 
diffraction was not suitable for data collection.   Taking all of this together, I decided to 
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create different mutants where I would redu ce the size of the “low complexity” region 
and test the mutant LipL1 activity in JEG3 and in in vitro assays.   
Four different m utants were m ade, deleting 11, 21, 31 or 37 resi dues from the low 
complexity region ( Figure 3A).  Although all four deleti on constructs rem oved the 
K264/E265 cut site, con structs d11LipL1, d21LipL1 and d31LipL1 still suffered fr om 
significant degradation.  The best behaved construct was d37LipL1, which was generated 
by removing almost the entire 47 residue lo w complexity region.  d37LipL1 still shows 
some minor degradation, but is far more stable than the full length construct (Figure 3B), 
allowing crystallization being m ore reproducible and yielding crystals  that diffract close 
to 4 Å, with hexagonal unit cell.  The trunc ated loop in d37LipL1 is not essential for 
lipoate ligase activity.  This construct lipoylates E. coli substrates when expressed in a 
lipoylation deficient E. coli cell line (Figure 3C) and lipoylates the H-protein in in vitro 
assays (Figure 3D). The following are conditions that we re optimized to express, purify 
and crystallize LipL1. 
1. flLipl1 (pMAL-LipL1) was m utated to generate pMAL-d11LipL1, pMAL-
d21LipL1 and pMAL-d31LipL1 using the prim ers in Table 1.  pMAL-
d31LipL1 was m utated to generate pMAL-d37LipL1 using the prim ers in 
Table 1. 
2. pMAL-d37 was transformed into BL21-Star (DE3) cells (Invitrogen) containing 
the pRIL p lasmid isolated from  BL21-CodonPlus-RIL cells (Agilent) and 
plasmid pRL586 encoding the Tobacco Etch Virus (TEV) protease.  
3. 2L of LB m edia were inoculated with 20 mL of overnight culture containing 
1% glucose and the an tibiotics ampicillin, kanamycin and chloram phenicol.  
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The cells were grown to an OD 600 around 1.0-1.2.  The tem perature was 
dropped to 27ºC and protei n production was induced with 0.4 m M IPTG for 5 
hours, and then the cultures were pelleted and stored at -20ºC. 
4. Cultures were lysed as described for flLipL1 (Chapter 4) and purified by m etal 
chelate affinity, cation exchange, an d gel filtration.  One major cons ideration 
was to run all columns in the same day to avoid further degradation.  
a. All buffers contained 20 mM HEPES at pH 7.5. 
i. Buffers for the m etal chelate affinity column (HiTrap Chelating 
HP, GE Healthcare) contained 100 mM NaCl.  Im purities were 
eluted with two 10 mL steps containing 10 m M and 30 m M 
imidazole followed by elution with a gradient to 500 mM  
imidazole in 50 m L.  LipL1 typically eluted around 160 m M 
imidazole. 
ii. Elution fractions from the chelating column were loaded onto 2x 
53 mL desalting colum ns (HiPrep Desalting 26/10, GE 
Healthcare) connected in tandem with a cation exchange column 
(HiTrap SP FF, GE Healthcare) .  After 65 mL, the desalting 
columns were disconnected and proteins were eluted from  the 
cation exchange column with a gradient to 1 M NaCl in 50 mL.  
LipL1 typically eluted around 200 mM NaCl. 
iii. Elution fractions from  the cation exchange colum n were 
concentrated to a volum e of 1-2 mL and loaded onto a gel 
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filtration column (S100 26/60, GE H ealthcare).  LipL1 typically  
eluted around 140 mL. 
5. Purified LipL1 protein was concentrated  to about 10 m g/mL.  The usual yield 
for 2L of culture was between 15-20 mg.   
6. Protein aliquots of 100 µL were stored at -80ºC.   
7. Crystallization attempt were conducted by hanging drop.  Two conditions were 
found for crystallization in the presence of two different ligands. 
a. Ligands 
i. 8-bromooctanoate  
ii. 6,8-dicholooctanote 
b. Conditions 
i. Sodium Formate (2.6-3.6 M) pH 6.0 and 7.0 
ii. Sodium Malonate (1.2-1.6 M) pH 7.0 and 7.5 
8. The mother liquor contained 500 µL of e ither of the above conditions  with or 
without 3% ethanol or 3% DMSO.  Glycerol did not help in crystallization. 
9. d37LipL1 was mixed with 2x excess of ligand and excess of Mg+2.  The protein 
was allowed to bind to the ligand for 5 minutes at room temperature followed 
by a high speed spin at 4 degrees to remove particulates.   
10. 1 µL of d37LipL1 was m ixed with 1 µL of mother liquor and trays were stored 
at 20ºC.  Crystal for mation was obser ved after 24 hours.  Cold te mperature 
(4ºC) did not help in crystallization. 
a. Micro- and macroseeding did not improve crystal quality. 
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11. Crystals formed after a f ew days ( 3-5 days) were tested  for diffraction and 
typically resulted in 4-8 Å resolution diffraction.   
a. Cryo conditions: 
i. Crystals formed in Sodium Malonate can be transferred to a drop 
containing 3.4 M Sodium Malonate. 
ii. Crystals formed in Sodium Formate can be transferred to a drop 
containing 5 M Sodium Formate. 
iii. Mother liquor plus 15% or 20% glycerol can also be used. 
iv. Ethylene glycol dissolves the crystals. 
b. Crystals were flash frozen in eith er liquid nitrogen to s hip to the  


























Figure 1.  Expression and purification of full length LipL1. Full length LipL1 can be 
expressed and purified with high yield.  However, some degradation occurs during 
purification, making crystallization attempts difficult.  A) SDS-PAGE of purified flLipL1 
after gel filtration.  Western blot analysis of degraded flLipL1, probed with α-His 
(antibody recognizes His-tag at N-terminus).  B)  Sequence alignment of PfLipL1 with E. 
coli ligase and bovine homologues shows that the low complexity region is only present 
in Pf.  C)  Amino acid sequencing reveals that the primary degradation produce has the 






















Figure 2. Crystallization attempts for flLipL1.  In some instances we were able to purify 
flLipL1 rapidly avoiding major degradation.  We found two conditions by which we can 
obtain crystals, both diffractable.  A) Crystals are shown obtained for flLipL1, in the 
presence of 8-bromooctanoate, with 3.4 M Sodium Formate at pH 6.0. B) Crystals are 
shown obtained for flLipL1, in the presence of 8-bromooctanoate, with 1.2 M Sodium 
Malonate at pH 7.0.  C) A diffraction pattern of the crystal shown in Figure 1A, with a 






Figure 3. d37LipL1 expression and purification attempts.  A) Sequence alignment of 
mutated region in LipL1: d11LipL1, d21LipL1, d31LipL1 and d37LipL1.  B)  SDS-
PAGE of both flLipL1 (left panel) and d37LipL1 (right panel) after gel filtration.  
d37LipL1 shows minor degradation, but is consistently is better behaved that flLipL1.  C)  
Complementation of E. coli lipoylation deficient cell line (Chapter 4).  Both flLipL1 and 
d37LipL1 are able to lipoylate endogenous E. coli substrates.  D)  Purified flLipL1 and 
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